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ACTIVATABLE NANOPROBES FOR
INTRACELLULAR DRUG DELIVERY

FIG. 2a shows a Qdot fluorescence emission spectra (excitation wavelength: 375 nm) measured as a function of time at
7.0 mM glutathione (GSH) concentration. These data show
that full restoration of Qdot fluorescence occurs within one
hour, after which no further increase in Qdot fluorescence
intensity is observed. The inset shows a plot ofQdot fluorescence intensity measured at the peak emission wavelength
(582 nm) as a function of time. This plot illustrates that the
fluorescence intensity plateaus at 60 minutes. The (red) line
of the plot is a non-linear fit to the data.
FIG. 2(b) shows a STAT-3 fluorescence emission spectra
(excitation wavelength: 300 nm) measured as a function of
time at 7.0 mM GSH concentration. These data show that full
restoration of STAT-3 fluorescence occurs within one hour,
after which no further increase in STAT-3 fluorescence intensity is observed. The inset shows a plot of STAT-3 fluorescence intensity measured at the peak emission wavelength
(430 nm) as a function of time. This plot illustrates that the
fluorescence intensity plateaus at 60 minutes. The (red) line
of the plot is a non-linear fit to the data.
FIG. 3a-3d includes phase-contrast (left panel) and corresponding epi-fluorescence (right panel) microscopy images
of: (a) MDA-MB-231 cells incubated with MMCNPs for 3
hours, showing significant Qdot fluorescence. This confirms
extensive folate receptor mediated uptake of the MMCNPs;
(b) MDA-MB-231 cells incubated with MMCNPs for 24
hours, again showing significant Qdot fluorescence that is
similar to the 3 hour incubation experiment. These data show
that uptake of MMCNPs and subsequent restoration of Qdot
fluorescence (indicative of STAT-3 release) occurs in less
than 3 hours; (c) control experiment performed with MDAMB-231 cells to which no MMCNPs were added. As
expected only a minor cellular autofluorescence is observed;
(d) control experiment performed with mouse thymus stromal epithelial cells, TE-71 incubated with MMCNPs for 24
hours. Similar to the control experiment shown in panel (c)
only background autofluorescence is observed at locations
that correspond to the locations of the cells, with no evidence
of uptake ofMMCNPs by the TE-71 normal cells. This control experiment validates that the delivery of MMCNPs is
highly targeted to MDA-MB-231 cells, which over-express
folate receptors.
FIGS. 4a-4c shows: (a) bright field; and (b) corresponding
epi-luminescence laser microscopy images ofMDA-MB-231
cells incubated with MMCNPs for 5 hours. The bright spots
in the fluorescence image indicate the location of aggregated
Qdots, revealing that the MMCNPs have reacted with intracellular GSH. After this reaction, the GSH coated Qdots are
somewhat hydrophobic innature leading to aggregation in the
intra-cellular environment. Most of the aggregates as they
appear in the bright field image (dark spots) and fluorescence
image (corresponding bright spots) are localized near the cell
membrane because of their hydrophobic nature. (c) Normalized ensemble fluorescence emission spectra acquired by
sample scanning laser confocal microscopy under 375 nm
laser excitation. The ensembles are constructed by averaging
fluorescence emission spectra obtained at different locations
inside individual cells under illumination with a diffraction
limited laser spots (-300 nm). Spectra were acquired at the
location of the Qdot aggregates (red line) and the cellular
regions without Qdots (autofluorescence, dark cyan line). As
a control, the same experiment was completed for Qdots in
the "OFF state" (black line) and "ON state" (blue line) on
glass substrates. Both the intra-cellular and extra-cellular
"ON state" Qdots appear slightly red shifted with respect to
the "OFF state" Qdots. In addition, the "ON state" Qdots are
significantly broadened at the blue edge as well as the red

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is related to U.S. Provisional Application
No. 61,495,992 filed Jun. 11, 2011. Priority to this application
is claimed under 35 USC §119, and is incorporated herein.
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STATEMENT OF GOVERNMENT RIGHTS
The work leading to this invention was partly supported by
grants from the NIH Grant No. 2P01HL059412-11Al and
NSF Grant No. 0506560. Accordingly, the govermnent may
have certain rights in the invention, as specified by law.
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FIELD OF THE INVENTION
The present invention relates to the field of activatable
nanoprobes, and in certain embodiments, to multifunctional
activatable nanoprobes.

20

BACKGROUND OF THE INVENTION
25

Cancer nanotechnology is a rapidly growing research area
in nanomedicine involving disease diagnostics and
therapy 1 •2 . During the past decade, engineered nanoparticles
integrated with multimodality/multifunctionality have
enabled imaging of cancer cells with high sensitivity and
demonstrated successful delivery of pre-loaded therapeutic
drugs in a targeted manner3- 7 . Multimodal nanoparticles that
are integrated with optical and magnetic imaging modalities8·9 have demonstrated strong potential to facilitate preoperative cancer diagnosis by MRI and optical based imaging 10 - 13 , to provide intra-operative surgical guidance (by
optically demarcating tumor tissue from healthy tissue), and
to track tumor metastasis 2 .7· 8.
Current nanoparticle technology allows for imaging of particles carrying therapeutic drugs 3 •6 .7• 10 •14•15 . However, no
activatable drug delivery system has been reported to date that
has demonstrated the ability to directly confirm intracellular
drug release upon reaction with a cytosolic biomolecule. Up
until now, challenges in designing and constructing a nanoparticle integrating imaging, monitoring, and therapeutic
functionalities in a single unit have restricted the fabrication
of such a nanoparticle system.

30
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BRIEF DESCRIPTION OF THE DRAWINGS
50

The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the
Office upon request and payment of the necessary fee.
FIG. la shows an optically activatable nanoprobe in an
"off' state and an "on" state in accordance with an aspect of
the present invention.
FIG. lb is a TEM image of various activatable multifunctional/multimodal composite nanoprobes (MMCNPs) showing nearly spherical particles with irregular surface morphology indicative of the presence of satellite quantum dots
(Qdots) on the IONPs (iron oxide nanoparticle core). The size
of the MMCNPs ranges from 20 nm to 40 nm, due to polydispersity of IONPs. The inset shows a high magnification
TEM image of a single MM CNP. The IONP can be discerned
in the image by its light grey contrast while the Qdots
appeared with dark contrast on the IONP surface.
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edge of the spectra, possibly due to the presence ofGSH on
the Qdot surface. The difference in the appearance of the red
shoulders in the intra-cellular and extra-cellular "ON state"
Qdots is most likely due to the difference in the environment.
The spectral feature around 500 nm in the intra-cellular "ON
state" Qdot fluorescence emission ensemble spectrum is due
the contribution of cellular autofluorescence.
FIGS. Sa-d show: (a) a schematic of agar phantom design.
The agar phantom consists of four layers. From bottom to top
these layers are: MDA-MB-231 cellsembeddedinagar(control), MMCNPs embedded in agar (control), MDA-MB-231
cells loaded with the MMCNPs embedded in agar (sample)
and agar layer, respectively. (b) a digital photograph of agar
phantom; and (c) a corresponding digital photograph of agar
phantom under 366 nm multi band UV irradiation. The MDAMB-231 cells loaded with the MMCNPs emit red fluorescence that is clearly visible to the naked eye. Control cells do
not show any detectable fluorescence emission. (d) an MRI
image ofagar phantom. The MDA-MB-231 cells loaded with
the MMCNPs show strong MRI signal (indicated with false
red color) in contrast with the control cells.
FIG. 6 shows results from a CyQuant® cell viability assay
performed on human breast (MB-MDA-231) and pancreatic
(Pane- I) cancer lines, and mouse thymus stromal epithelial
line, TE-71. Cells were untreated (Control) or treated for 24
hours with MMCNPs to which no STAT-3 inhibitor was
attached (RII 61), STAT-3 inhibitor only (Compound), and
MMCNPs (RII 64). Compared to untreated (Control), the
viability of cells treated with MMCNPs to which no STAT-3
is attached (RII 61) was attached is not significantly different,
indicating that the MMCNP itself do not compromise cell
viability. By contrast, the cells treated with 50 µM STAT-3
inhibitoronly (Compound) showed about a 15-20% decrease
in cell viability, while cells treated with fully functional
MMCNPs to which STAT-3 inhibitor was attached showed
nearly 30% decrease in cell viability, even though the amount
of STAT-3 inhibitor contained in the about 5 µg of MMCNP
administered in about 100 µL of cell media was expected to be
less than the about 50 µM that was directly added to the cells
in the other study. This key observation demonstrates the
effectiveness of the reported nanoparticle design in highly
targeted drug delivery to the cancer cells while maximizing
cancer cell death with reduced amounts of drugs used compared to conventional approaches. Even though the MMCNP' s consume much less STAT3 drug, the delivery efficiency
is dramatically increased, thus resulting in increased therapeutic efficiency while minimizing the potential for medical
side effects due to the presence of excess free drug.
FIG. 7 is a high resolution TEM (HRTEM) image of a
single MMCNP. Individual satellite Qdots on the IONP surface can be clearly identified by their single crystalline structure while the IONP (iron oxide nanoparticle core) in the
HRTEM image is obscured by the satellite Qdots.
FIG. 8 shows FT-IR spectra of (a) dihydrolipoic acid, (b)
lipoic acid, (c) dihydrolipoic acid coated IONPs, and (d)
IONPs. The broad band at 3200-3600 cm-1 indicates the
surface hydroxyl group of the super paramagnetic IONPs
(Figure S4d). The bands at about 3046 (0-H), about 2934
(--CH2-), about 1697 (C=O), about 1252 (0-H), and
about 935 (OH) cm- 1 were observed for dihydrolipoic acid
and lipoic acid in (a) and (b) respectively. The presence of
these characteristic bands into the spectra of dihydrolipoic
acid coated IONPs (c) confirmed the dihydrolipoic acid coating on the surface ofIONPs.
FIG. 9 shows normalized UV-Vis absorbance spectra of
pure Qdots (red), IONP (black), Qdots attached to IONP
(green) and MMCNPs (blue). After Qdots are attached to

IONPs, a large red shift of the absorption spectrum is
observed, indicating successful attachment of satellite Qdots
to IONP core. The attachment of STAT-3 to form MMCNPs
leads to a narrowing of the UV-Vis spectrum and the slight
blue shift in comparison to IONP-Qdot construct.
FIG. 10 shows a normalized emission spectra of pure
Qdots (red), IONP (black), Qdots attached to IONP (green)
and MMCNPs (blue). Only a blue shift of the MMCNPs with
respect to the free Qdots and the IONP-Qdot construct is
observed.
FIG.11showsa3D plot of the Qdot fluorescence intensity
recovery from MMCNP ("OFF state") as a function of time
for GSH concentrations ofabout 2.8, about 4.2, about 5 .7, and
about 7 .0 mM. Even at the lowest GSH concentration, the
Qdot fluorescence recovers in approximately 1 hour. Furthermore, the timescale of fluorescence recovery appears to be
independent of GSH concentration higher than about 1.4
mM. Since the intra-cellular concentration of GSH ranges
from about 1 mM to about 15 mM, it is expected that
MMCNP uptaken by the cancer cells will release its cargo
intracellularly (e.g., drug) within about an hour.
FIG. 12 is a TEM image of a plurality ofIONPs showing
polydispersity. Bar=20 nm.
FIG. 13 is a 3D reconstruction of MRI images recorded on
agar phantom. This demonstrates the appearance of strong
MRI signal from the MDA-MB-231 cells loaded with the
MMCNPs (indicated with false red color).
FIG. 14 shows another embodiment of an optically activatable nanoprobe (DNCP) in accordance with an another aspect
of the present invention.
FIG. 15 shows a plurality of STAT3 inhibitors for use with
nanoparticles in accordance with an aspect of the present
invention.
FIG. 16 illustrates an exemplary NAC-modified STAT3
inhibitor.
FIG. 17 is a schematic illustrating sensing of cargo release
by a Qdot core due to intracellular GSH.
FIGS. l8a-b shows a nanoparticle having a CdS:Mn/ZnS
quantum dot core, to which an S3I inhibitor drug will be
covalently linked via a cleavable disulfide bond linkage. (a) a
lipid bilayer may be overcoated on the surface of the S3I
conjugated CdS:Mn/ZnS quantum dots. (b) the lipid bilayer
may be further functionalized with folic acid to target cancer
cells that overexpress folate receptors, or with TAT peptide (a
cell-penetrating peptide).
FIGS. l9a-c show (a) anAFM image of zwitterionic (DCS,
9PC) lipid vesicles and chemical structures of (b) DOTAP and
(c) PtdEtn.
FIG. 20 shows the effect of an increase of EDTA concentration on the fluorescence intensity ofGSH-Qdot.
FIG. 21 shows the effect of an increase of Cu ion concentration on the fluorescence intensity ofGSH-Qdot.
FIG. 22 shows the effect of an increase of EDTA concentration on the fluorescence intensity of a NAC-Qdot.
FIG. 23 shows the effect of an increase of Cu ion concentration on the fluorescence intensity of a NAC-Qdot.
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The present inventors have developed new and unique activatable nanoprobes that may deliver active agents, and in
some embodiments, may also be optically and magnetically
imageable, targetable, and/or capable of reporting on intracellular drug release events. In one particular exemplary
embodiment, an optically activatable nanoprobe is provided
that comprises an inorganic core, e.g., a super-paramagnetic
iron oxide nanoparticle core (IONP), associated with satellite

US 8, 791,285 B2
5

6

quantum dots (Qdots), e.g., CdS:Mn/ZnS quantum dots,
where the Qdots themselves are further functionalized with
an active agent, a targerting agent, and a hydrophilic dispersing agent. Advantageously, the Qdot luminescence is
quenched in this nanoprobe ("OFF" state) due to combined
electron/energy transfer mediated quenching processes
involving IONP, targeting agent and active agents. Upon
intracellular uptake, the nanoprobe is exposed to a cytosolic
glutathione (GSH)-containing environment resulting in restoration of the Qdot luminescence ("ON" state), which
reports on uptake and drug release. Probe functionality was
validated using fluorescence and MR measurements, as well
as in vitro studies using cancer cells that overexpress folate
receptors.
It is important to an understanding of the present invention
to note that all technical and scientific terms used herein,
unless defined herein, are intended to have the same meaning
as commonly understood by one of ordinary skill in the art.
The techniques employed herein are also those that are known
to one of ordinary skill in the art, unless stated otherwise.
Prior to setting forth the invention in detail and for purposes of
more clearly facilitating an understanding the invention as
disclosed and claimed herein, the following definitions are
provided.
As used herein, the terms "about" and "approximately" as
used herein refers to-values that are ±10% of the stated
value.
As used herein, the term "active agent" includes any synthetic or natural element or compound, which when introduced into a mammal causes a desired response, such as an
optical or biological response.
As used herein, the term "activatable" refers to an agent
capable of being released from an associated substrate, e.g.,
core, upon exposure to a predetermined compound. For
example and without limitation, an activatable active agent
may include an active agent that is released from a core
component upon exposure to an endogenous molecule, such
as glutathione, that cleaves a bond between the active agent
and the core component.
As used herein, the term "aptamer" refers to any oligonucleic acid or peptide molecules that bind to a specific target
molecule.
As used herein, the terms "chitosan" or "chitosan polymer"
refer to chitosan (also known as poliglusam, deacetylchitin,
poly-(D)glucosamine) and any derivatives thereof. The chitosan polymer is typically composed of a linear polysaccharide of randomly distributed ~-(1-4 )-linked D-glucosamine
(deacetylated unit) and/or N-acetyl-D-glucosamine (acetylated unit) units. The general terms "chitosan" or "chitosan
polymer" as used herein may also refer to chitosan or chitosan
having one or more molecules attached thereto, e.g., bonded,
or conjugated, thereto, such as an imaging agent, a targetspecific ligand, or a biologically active compound. Exemplary derivatives of chitosan include trimethylchitosan
(where the amino group has been trimethylated) or quaternized chitosan. Advantageously, chitosan has a plurality of
amine functional groups, which as set forth below, may be
utilized for the attachment of various agents thereto, such as
imaging agents, target-specific ligands, and/or biologically
active agents.
As used herein, "folate species" or "folate" refers to folate,
folic acid, derivatives thereof, or analogs thereof.
As used herein, the terms "bonded," "linked," "labeled,"
"attached," "conjugated," and variations thereof are intended
to be used interchangeably and may refer to covalent, ionic,
Van der Waals, or hydrogen bonding, for example.

As used herein, the term "hydrophilic" refers to any substance having an affinity for water and tending to dissolve in,
mix with, or swell in a water or aqueous medium.
As used herein, the term "hydrophobic" refers to any substance not having an affinity for water and tending not to
dissolve in, mix with, or swell in a water or aqueous medium.
As used herein, the term "surfactant" refers to a wetting
agent that lowers the surface tension of a liquid, thereby
allowing easier spreading and the lowering of the interfacial
tension between two liquids.
As used herein, the term "STAT" refers to signal transducers and activators of transcription, which represent a family of
proteins that, when activated by protein tyrosine kinases in
the cytoplasm of the cell, migrate to the nucleus and activate
gene transcription.
In accordance with one aspect of the present invention,
there is provided an activatable nanoprobe comprising a core
component and an active agent associated with the core component via a bond configured to be cleaved upon exposure to
an endogenous compound.
In accordance with one aspect, there is provided an activatable nanoprobe comprising a core component and an activatable active agent associated with the core component. A
lipid vesicle at least partially or fully encases the activatable
agent and the core component.
In accordance with another aspect, there is an optically
activatable nanoprobe comprising an inorganic core and a
Qdot linked to the inorganic core. At least one ligand is linked
to the Qdot. The one or more ligands, which are typically
electron-rich, are effective to reduce luminescence of the
quantum dot when linked thereto. In this way, the Qdot luminescence is quenched in this nanocomposite probe ("off
state") due to electron/energy transfer quenching processes
between the inorganic core and the at least one ligand. In one
embodiment, the at least one ligand comprises at least one of
a biologically active agent, a targeting agent, a hydrophilic
dispersing agent, or combinations thereof.
In accordance with another aspect, there is provided an
optically activatable nanoprobe for monitoring intracellular
drug delivery. The nanoprobe comprises a core component;
and at least one ligand linked to the core component. The at
least one ligand comprises at least one of an active agent, a
targeting agent, an imaging agent, a hydrophilic dispersing
agent, and combinations thereof. The at least one ligand is
effective to reduce luminescence of the quantum dot when
linked thereto.
In accordance with another aspect, there is provided an
optically activatable nanoprobe for monitoring intracellular
drug delivery. The optically activatable nanoprobe comprises
an inorganic core and a plurality of quantum dots linked to the
inorganic core. A plurality of ligands are linked to respective
ones of the plurality of quantum dots. The plurality ofligands
include each of a biologically active agent, a targeting agent,
and a hydrophilic dispersing agent. Since the ligands are
electron rich, the ligands collectively reduce luminescence of
the of the quantum dot when linked thereto.
In accordance with another aspect, there is provided an
optically activatable nanoprobe comprising a quantum dot
core and at least one ligand linked to the quantum dot core. A
chitosan-based shell surrounds the quantum dot core and the
at least one ligand.
In accordance with another aspect, there is provided a
method for monitoring intracellular drug delivery within a
subject. The method comprises administering to the subject
an effective amount of an optically activatable nanoprobe.
The optically activatable nanoprobe comprises an inorganic
core, a plurality of quantum dots linked to the inorganic core,
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and at least an active agent linked to the respective ones of the
quantum dots. Upon intracellular uptake of the nanoprobe, a
linkage between the active agents and the quantum dots is
cleaved to allow the plurality of quantum dots to transfer from
a quenched state, wherein the luminescence of the plurality of
quantum dots is quenched, to a luminescent state, wherein the
luminescence of the plurality of quantum dot is activated. In
one embodiment, the method further comprises detecting a
presence of the plurality of quantum dots, wherein an increase
in luminescence of the plurality of quantum dots is indicative
of a release of the active agent intracellularly. In one embodiment, the at least one ligand comprises each of an active
agent, a targeting agent, an imaging agent, and a hydrophilic
dispersing agent, or a combination thereof.
In yet another aspect, there is provided a method for monitoring intracellular drug delivery within a subject. The
method comprises administering to the subject an effective
amount of an optically activatable nanoprobe. The optically
activatable nanoprobe comprises a core component comprising a quantum dot and an active agent linked to the quantum
dot. Upon intracellular uptake of the nanoprobe, a linkage
between the active agent and the core component is cleaved to
allow for release of the active agent and to allow the quantum
dot to transfer from a quenched state, wherein the luminescence of the plurality of quantum dot is quenched, to a luminescent state, wherein the luminescence of the plurality of
quantum dots is activated. The method further comprises
detecting a presence of the quantum dot, wherein an increase
in luminescence of the quantum dot is indicative of a release
of the active agent intracellularly.
In yet another aspect, there is provided an activatable nanoprobe comprising a core component; an activatable active
agent associated with the core component; and a lipid vesicle
at least partially or fully encasing the activatable agent and the
core component.
In still another aspect, there is provided an optically activatable nanoprobe comprising: an inorganic core; a plurality
of quantum dots about the inorganic core and linked to the
inorganic core; and a hydrophilic dispersing agent linked to
respective ones of a plurality of the quantum dots.
In still another aspect, there is provided a method for making optically activatable nanoprobes. The method comprises
obtaining a plurality of nanoparticles comprising an inorganic core and obtaining a plurality of quantum dots. Further,
the method comprises linking the plurality of quantum dots to
the inorganic core; and linking an active agent, a targeting
agent, and a hydrophilic dispersing agent to respective ones of
the plurality of quantum dots.
In yet another aspect, there is provided a method for monitoring intracellular drug delivery within a subject in whom an
effective amount of an optically activatable nanoprobe has
been administered. The optically activatable nanoprobe comprises an inorganic core; a plurality of quantum dots linked to
the inorganic core, and at least one ligand linked to respective
ones of the plurality of quantum dots, the at least one ligand
comprising at least an active agent linked to the quantum dot
by a linkage; and wherein, upon intracellular uptake of the
nanoprobe, a linkage between the active agent and a respective quantum dot is cleaved to allow for release of the active
agent and to allow the plurality of quantum dots to transfer
from a quenched state, wherein the luminescence of the plurality of quantum dots is quenched, to a luminescent state, and
wherein the luminescence of the plurality of quantum dot is
activated. The method further comprises confirming release
of the biologically active agent by detecting a presence of the
plurality of quantum dots in the luminescent state.

In yet another aspect, there is provided an optically activatable nanoprobe comprising a core component comprising
a quantum dot; and a coating comprising a hydrophilic dispersing agent at least partially surrounding the core component.
In certain aspects, the nanoprobes include a core component. In one embodiment, the core component comprises an
inorganic core, which allows for the attachment of a plurality
of a Qdots to be disposed about the inorganic core. In this way,
a single activatable nanoprobe may have a plurality of quantum dots attached thereto for signal enhancement in monitoring applications. In one embodiment, the inorganic core comprises a paramagnetic material. In a particular embodiment,
the inorganic core comprises iron oxide. A super-paramagnetic iron oxide nanoparticle is an excellent MRI contrast
agent (also called a T2 contrast agent). Utilizing iron oxide in
the inorganic core facilitates imaging ofMMCNPs by MRI. It
also assists in purification, as an external permanent magnet
can be implemented to separate MMCNPs magnetically from
the reaction mixture.
The Qdots may comprise a semiconductor crystal whose
size is on the order of just a few nanometers and that exhibits
quantum confinement. Typically, Qdots contain anywhere
from about 100 to about 1,000 essentially free electrons and
range from about 2 nm to about 10 nm in size, or about 10 to
about 50 atoms, in diameter. One of the optical features of an
excitonic Qdot noticeable to the unaided eye is coloration.
While the material which makes up a quantum dot is significant, more significant in terms of coloration is the size. The
larger the Qdot, the redder (the more towards the longer
wavelength end of the electromagnetic spectrum) they fluoresce. The smaller the Qdot, the bluer (the more towards the
short wavelength end) it is. The coloration is directly related
to the energy levels of the Qdot. Quantitatively speaking, the
band gap energy that determines the energy (and hence color)
of the fluoresced light is approximately inversely proportional to the square of the size of the Qdot. Larger Qdots have
more energy levels, which are more closely spaced. This
allows the Qdot to absorb photons containing less energy,
e.g., those closer to the red end of the spectrum.
In certain embodiments, the Qdots include a semiconductor nanocrystal core and a wide band-gap semiconductor
nanocrystalline shell (coating) disposed on the surface of the
nanocrystal core, which is typically different from the material used for the nanocrystal core. The semiconductor coating
may define a fully or partially passivating semiconductor
coating layer. Exemplary materials for the nanocrystal core
and the semiconducting coating of the quantum dot include,
but are not limited to, zinc sulfide, zinc selenide, zinc telluride, cadmium sulfide, cadmium selenide, cadmium telluride,
mercury sulfide, mercury selenide, mercury telluride, magnesium telluride, aluminum phosphide, aluminum arsenide,
aluminum antimonide, gallium nitride, gallium phosphide,
gallium arsenide, gallium antimonide, indium nitride, indium
phosphide, indium arsenide, indium antimonide, aluminum
sulfide, lead sulfide, lead selenide, germanium, silicon, other
group II-group VI compounds, group III-group V compounds, group IV compounds, and alloys, compounds, or
mixtures thereof. In one embodiment, the semiconductor
coating has a band gap greater than the band gap of the
nanocrystal core. In some embodiments, the core material can
also be doped with one or more suitable dopants, such as
manganese (Mn) or copper (Cu). In the examples below, a
nanoprobe comprising an iron oxide nanoparticle core associated with satellite CdS:Mn/ZnS Qdots was formed,
although it is understood the present invention is not so lim-
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ited. In another embodiment, the Qdots may comprise ZnS:
Mn/ZnS Qdots (non-heavy metal containing Qdots such as
cadmium or arsenic).
In particular embodiments, a coupling agent may be provided to link the Qdots to the inorganic core. In one embodiment, the coupling agent comprises a heterobifunctional
cross-linking compound that can link to the inorganic core at
one location thereon and can link to a respective Qdot at a
location thereon. In one embodiment, the coupling agent
comprises dihydrolipoic acid (DHLA), which can link the
inorganic core thereto through its carboxyl end and link to a
respective Qdot via its bidentate thiol bonds.
Either or both of the inorganic core or the quantum dots can
be modified with the coupling agent prior to addition of the
other of the components. In one embodiment, the coupling
agent is provided as a coating over the inorganic core. As set
forth below, in one embodiment, to minimize the possibility
of cross-linking when using a coupling agent, e.g., DHLA,
the addition of the modified inorganic core particles to
unmodified quantum dots may be done slowly and in a controlled manner.
When the ligand comprises a targeting agent, the targeting
agent may be any compound having an affinity for a predetermined molecular target. In one embodiment, the targeting
agent comprises a folate species, which may be folate, folic
acid, or derivatives thereof. Examples of folate derivatives
include, but are not limited to, dihydrofolate, tetrahydrofolate, S-methyl-tetrahydrofolate and S,10-methylene tetrahydrofolate. Humans and other manmials express a number
of proteins that bind to folate and transport it into cells. For
example, in humans, alpha and beta folate receptors have
been identified, each of which can occur in several isoforms
(e.g. as a result of differential glycosylation). These proteins
are referred to as "folate receptors." Thus, a folate receptor is
considered to be any protein expressed on the surface of a cell,
such as a cancer cell, which binds folate in preference to other
moieties or compounds. In one embodiment, the targeting
agent is selected to specifically target these folate receptors in
a mammalian subject.
Additionally, in other embodiments, the targeting agent
may be one or more of an aptamer, a peptide, an oligonucleotide, an antigen, an antibody, or combinations thereofhaving
an affinity for a predetermined molecular target. In one
embodiment, the predetermined molecular target is associated with a cancer cell, a leukemia cell, an acute lymphoblastic leukemia T-cell, or combinations thereof. In a particular
embodiment, the ligand comprises an aptamer having an
affinity for leukemia cells, e.g., an acute lymphoblastic leukemia T-cell. The aptamer may include any polynucleotideor peptide-based molecule, for example. A polynucleotidal
aptamer is a DNA or RNA molecule, usually comprising
several strands of nucleic acids that adopt highly specific
three-dimensional conformation designed to have appropriate binding affinities and specificities towards specific target
molecules, such as peptides, proteins, drugs, vitamins, among
other organic and inorganic molecules. Such polynucleotidal
aptamers can be selected from a vast population of random
sequences through the use of systematic evolution ofligands
by exponential enrichment. A peptide aptamer is typically a
loop of about 10 to about 20 amino acids attached to a protein
scaffold that bind to specific ligands. Peptide aptamers may
be identified and isolated from combinatorial libraries, using
methods such as the yeast two-hybrid system. In one embodiment, the ligand comprises the DNA aptamer sgc8c having a
sequence according to SEQ. ID No. 1:
S'-ATC TAA CTG CTG CGC CGC CGG GAAAAT ACT
GTA CGG TTA GA-3'.

The DNA aptamer sgc8c has been shown to have a particular binding affinity for leukemia cells, e.g, acute lymphoblastic leukemia T-cells.
When the ligand comprises a hydrophilic dispersing agent,
the hydrophilic dispersing agent may be directly or indirectly
linked to respective ones of the quantum dots. In addition,
when the ligand comprises a hydrophilic dispersing agent, the
hydrophilic dispersing agent may comprise any compound
that will increase a hydrophilicity of the nanoprobe relative to
a nanoprobe without the hydrophilic dispersing agent. Exemplary hydrophilic dispersing agents include but are not limited to one or more of NAC (N-Acetyl-L-Cysteine (NAC),
glutathione (GSH), PEG (polyethylene glycol), m-PEG, PPG
(polypropylene glycol), m-PPG, PGA (polyglutamic acid),
polysialic acid, polyaspartate, polylysine, polyethyeleneimine, biodegradable polymers (e.g., polylactide, polyglyceride ), and functionalized PEG, e.g., terminal-functionalized
PEG, and structural analogues of any of the above compounds.
In one embodiment, the hydrophilic dispersing agent is
indirectly linked to respective ones of the quantum dots
through a spacer or linking compound. For example, as will
be explained below, in a particular embodiment, a NAC
(N-Acetyl-L-Cysteine)-modified ethylenediamine ligand
(NAC-EDA modified ligand) is first linked to the quantum dot
surface via the sulfide groups ofNAC. Thereafter, the surface
amine groups provided by NAC-EDA may be reacted with an
N-hydroxysuccinimide (NHS) ester derivative of methylpoly-ethylene glycol (MPEG-NHS ester) to improve overall
dispersability of the nanoprobe.
In a particular embodiment, a plurality of hydrophilic dispersing agents are linked to a plurality of the Qdots so as to
define a hydrophilic shell or coating for the nanoprobe. In one
embodiment, a hydrophilic shell or coating is formed by
linking a plurality of hydrophilic dispersing molecules to a
plurality of Qdots surrounding the inorganic core. It is appreciated that other ligands may be attached to the Qdots as
described herein, e.g., an active agent or a target agent, and
that the hydrophilic shell or coating may not be continuous.
Typically, the coating or shell will at least partially surround
the inorganic core. In one embodiment, the hydrophilic dispersing agent comprises GSH. In another embodiment, the
hydrophilic dispersing agent comprises NAC. As set forth in
the Example, the present inventors have found that GSH and
NAC are at least capable of coating a Qdot surface via conjugation through their sulfhydryl (-SH) groups, and thus
form "hydrophilic Qdots" or "hydrophobic nanoprobes."
Both GSH-Qdots and NAC-Qdots, and particularly NACQdots, may be an attractive choice for the fabrication of
activatable ("OFF/ON") Qdots for bioimaging and sensing
applications.
When the ligand of the optically activatable nanoprobe
comprises an active agent, the active agent may include any
compound or composition that produces a preventative, healing, curative, stabilizing, ameliorative or other beneficial
therapeutic effect. In a particular embodiment, the active
agent is a STAT inhibitor, such as a STAT-3 inhibitor.
Examples of manmialian STAT inhibitors include inhibitors
ofSTAT-1, STAT-2, STAT-3, STAT-4, STAT-Sa, STAT-Sb, and
STAT-6. In one embodiment, the active agent is one or more
ofBP-1-102, SF-1066 and S31-201, all of which have proven
activity against STAT-3 with IC 50 values of 6.8, 3S, and 86
µm, respectively.
STAT-3, in particular, is an oncogene constitutively activated in many cancer systems where it contributes to carcinogenesis. The signal transducers and activators of transcription
(STATs) are a class of transcription factor proteins that regu-
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4,7-tryl)triaceticacid). Gd3 + ions are paramagnetic and
late cell growth and survival. A total of seven STAT isoforms,
DOTA is a chelator of Gd ion. The Gd-DOTA is paramagnetic
encoded in distinct genes, have been identified in mammalian
cells. STAT-3 protein isoform is known to directly up-regulate
agent and it provides MRI contrast. Gd-DOTA is commercially available under the brandname ProHance® (also called
Bcl-xL, Mcl-1, cyclin Dl/D2 and c-myc, contributing to
compromised regulation by stimulating cell proliferation and 5 Gadoteridol). In another embodiment, the imaging agent may
preventing apoptosis in numerous human cancers including
comprise iohexyl.
breast, prostate, melanoma, lung, brain, pancreatic, ovarian,
In accordance with one aspect of the invention, the
colon cancers. STAT-3 activation occurs via phosphorylation
ligand(s) (e.g., a targeting agent, dispersing agent, and/or an
of tyrosine 705, which promotes STAT dimer formation
active agent), the cross-linker or spacing compound, and/or
through STAT phosphotyrosine-SH2 domain interactions. 10 the Qdot may be modified with a compound that increases the
These STAT dimers translocate to the nucleus, where they
functionality and/or dispersability of the optically activatable
regulate gene expression. Constitutive STAT-3 activity medinanoprobe in aqueous solutions, particularly at pH of 7.4. In
ates dysregulated growth and survival, angiogenesis, as well
one embodiment, the ligand(s) (e.g., a targeting agent, disas suppresses the host's immune surveillance of tumors and
persing agent, and/or an active agent), the linking or spacing
represents a valid target for small molecule anti-cancer 15 compound, and/or the quantum dot may be modified with
NAC (N-Acety1-L-Cysteine). NAC-modification of the Qdot,
design. The STAT-3 inhibitor for use in the present invention
may be any known inhibitor of STAT3 known in the art.
ligand, or linking/spacing molecules has several advantages:
Exemplary STAT3 inhibitors are disclosed in U.S. Published
(i) NAC passivates the Qdot surface via formation of stable
Patent Application Nos. 20100310645, 20090318367,
disulfide bonds, resulting in increased quantum efficiency; ii)
20090069420, 20080187992, 20070123502, 20050074502, 20 NAC improves aqueous dispersability of the nanoprobes; and
iii) NAC provides surface carboxyl groups for functionalizaand 20050004009, the entirety each of which is incorporated
tion with other desired ligands.
by reference herein. Typically, the STAT-3 inhibitor will
The below description further describes exemplary
include a sulfur-containing functional group, which may
embodiments of an optically activatable nanoprobe in accorform a covalent disulfide bond with the Qdot to form a linkage
25 dance with the present invention and a method for making the
between the STAT-3 inhibitor and the Qdot.
The optically activatable nanoprobes described herein may
same. It is understood that the present invention, however, is
not limited to the below-described optically activatable nanothus be utilized to monitor and/or treat any proliferation disprobes, and that the nanoprobes may include one, two, or
order characterized by the over-activation of a STAT protein.
more of the ligands described below attached to the Qdots,
In one embodiment, the proliferation disorder to be treated is
a cancer producing a tumor characterized by over-activation 30 may include other linked compounds, and may be further
of STAT!, STAT3, STATS, or a combination of two or all
modified as necessary for the particular application.
In one embodiment, as shown in FIG. la, the optically
three of the foregoing. Examples of such cancer types
include, but are not limited to, breast cancer, ovarian cancer,
activatable nanoprobe (MMCNP) comprises a super-paramultiple myeloma and blood malignancies, such as acute
magnetic ironoxidenanoparticle core (IONP; -5-20 nm size)
myelogenous leukemia. In addition to cancer, the prolifera- 35 and satellite CdS:Mn/ZnS quantum dot (Qdots; -3.5 nm size)
shell. Each Qdot is attached to the core IONP by a heterotion disorder to be treated using the compounds, compositions, and methods of the invention can be one characterized
bifunctional cross-linker molecule, dihydrolipoic acid
(DHLA). The DHLA connects the IONP through its carboxyl
by aberrant STAT-3 activation within cells associated with a
non-malignant disease, pathological state or disorder (collecend and to the Qdot via its bidentate thiol bonds. To minimize
tively "disease"), and likewise comprising administering or 40 the possibility of cross-linking, the IONP-Qdot conjugation
contacting the cells with a an effective amount of one or more
strategy involved controlled addition of DHLA modified
STAT3 inhibitors to reduce or inhibit the proliferation.
IONP to unmodified Qdots as described in the Example
In still other embodiments, the active agent may include
below. The carboxyl and the thiol functional groups are compeptides (e.g., RGD peptide, integrin selective; see
patible with the IONP and Qdot particle surfaces, respecDechantsreiter, M.A., et al., N-Methylated Cyclic RGD Pep- 45 tive1s.24-26.
tides as Highly Active and Selective av~3 Integrin AntagoUpon attachment of a Qdots to an IONP nanocrystal, a
nists. Journal of Medicinal Chemistry, 1999. 42(16): p. 3033large surface area still remains available on the satellite Qdots
3040.), antibodies (e.g., CDlO monoclonal antibody for
for further surface modification and conjugation. Next, an
targeting human leukemia; see Santra, S., et al., Conjugation
N-Acetyl-L-Cysteine (NAC)-modified STAT3 inhibitor
of Biomolecules with Luminophore-Doped Silica Nanopar- 50 (NAC-STAT3; a therapeutic model drug), a NAC-modified
ticles for Photostable Biomarkers. Analytical Chemistry,
fol ate (NAC-FA; a cancer targeting agent) and an NAC-modi2001. 73(20): p. 4988-4993.) and proteins. When the optified ethylenediamine (NAC-EDA, an amine modified ligand)
cally activatable nanoprobes comprise a biologically active
were separately synthesized. As set forth above, NAC-medidrug, as well a target-specific ligand, the disclosed nanoated surface modification ofQdots has several advantages: (i)
probes are useful as target-specific drug delivery vehicles.
55 it passivates the Qdot surface via formation of stable disulfide
The imaging agent may comprise one or more of a fluorobonds, resulting in increased quantum efficiency, (ii) it
phore, iohexy1, and a paramagnetic chelate having a paramagimproves aqueous dispersibility ofQdots, and (iii) it provides
netic ion bound therein. In another embodiment, the imaging
surface carboxyl groups for functionalization with other
agent may be a fluorophore and/or a paramagnetic chelate
desired ligands. Furthermore, this approach reflects the
(chelator) having an MRI (magnetic resonance imaging) con- 60 uniqueness of the reported MMCNP design, where the sepatrast agent bound therein. The MRI contrast agent may comrate synthesis of each of these ligands allows for control of the
prise a paramagnetic ion selected from one or more of gadoratio of these ligands when attaching to Qdots or substitution
linium, dysprosium, europium, and compounds, or
of one of these ligands, resulting in a fully modular design of
combinations thereof, for example. In one embodiment, the
the MMCNP (akin to a nanoparticle LEGO®). After IONPparamagnetic ion comprises a gadolinium ion and the chela- 65 Qdot conjugation, further surface conjugation reactions were
tor is a DOTA-NHS ester (2,2',2"-(10-(2-(2.5-dioxopyrroliperformed by treating IONP-Qdot with a mixture of NACSTAT3, NAC-FA and NAC-EDA. The surface modification
din-1 yloxy)-2-oxoethyl)-14, 7, 1O-tetraazacyclododecane-1,
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procedures are detailed in Examples below. The surface
amine groups (provided by NAC-EDA) were reacted with the
N-hydroxysuccinimide (NHS) ester derivative of methylpoly-ethylene glycol (MPEG-NHS ester; a biocompatible
highly-hydrophilic dispersing agent) to improve overall dispersibility of the MMCNPs.
A STAT-3 drug and folate (FA) were intentionally selected
as electron-rich ligands that can substantially quench Qdot
fluorescence. Substantial quenching typically refers to
75-100% quenching of fluorescence. In a more specific
embodiment, substantial quenching refers to 90-100% fluorescence quenching. This selection process involved mixing
of each of these ligands with Qdots followed by observation
of the extent of luminescence quenching (data not shown).
Each of these ligands thus serves a dual purpose. The treatment ofIONP-Qdots with NAC-STAT3 and NAC-FA drastically reduced the fluorescence of the Qdots. It was noted that
NAC itself did not quench Qdot luminescence, thus justifying
the combined role ofSTAT-3 drug and FA as quenchers. As a
result, the MM CNP is essentially in a fluorescently quenched
("OFF") state when the ligand(s) are attached to the Qdots. It
is understood that by "OFF," however, it is not necessarily
meant the nanoprobe is 100% quenched or does not exhibit
some luminescence, but only that the amount of luminescence is greater when the ligand(s) are not attached vs.
attached. The luminescence of the MMCNPs is restored
("ON" state) upon treatment with an appropriate cleaving
agent, which effectively cleaves disulfide bonds between the
ligand and the IONP-Qdots, such as glutathione (GSH).
The morphological, optical, and magnetic properties of
MMNCPs were extensively characterized. TEM studies confirm the formation of about 20-40 nm size nanocomposites as
shown in FIG. lb. The IONP core and satellite Qdots surrounding the core are clearly visible with low resolution TEM
(FIG. lb), whereas magnified TEM images clearly show
Qdots around the IONP (FIG. lb inset). HRTEM also confirms the single crystalline structure of the Qdots (FIG. 7)
surrounding the core IONP. Inductively coupled plasma
analysis of the sample confirms the presence of Zn (about 41
wt%), Fe (about 6.2 wt%) and Cd (about 10 wt%) with a
relative ratio of about 6.6: 1.0: 1.6 (WAN). Zeta potential (s)
measurements correlate with particle surface charge. The I;
values ofIONP, IONP-DHLA, IONP-Qdots-STAT3-FA and
IONP-Qdot-STAT3-FA-m PEG are about -20 mV, about
-4.0 mV, about -17 mV and about -21 mV, respectively. As
expected, DHLA modification of the iron oxide nanoparticle
core (IONP) drastically reduced its surface charge due to
reduction of the negative surface charge of the IONP. Further
surface modification with the STAT-3 drug and folic acid
(folate) resulted in an increase in the overall negative surface
charge on the particle. This is likely due to the presence of
carboxyl groups on the folate residues on the particle surface.
Pegylation with biocompatible mPEG, however, showed
minimal effect on the particle surface charge due to its neutral
nature. It was observed that pegylated particles exhibited
good phosphate buffer dispersibility. A comparative analysis
of FT-IR spectra of dihydrolipoic acid (DHLA) (a), lipoic
acid (b ), DHLA-coated IONPs (c ), and IONPs (d) confirmed
successful surface modification of IONP with DHLA (FIG.
8). Fluorescence spectroscopy in solution was used to investigate the Qdot luminscence properties at different stages of
MM CNP development as well as for tracking the drug release
events.
Glutathione (GSH), a tripeptide biomolecule found in all
animal cells at relatively high cytosolic concentration (about
1-10 mM27 •28 , reduced form), effectively reduces disulfide
bonds and in this process glutathione is converted to glu-

tathione disulfide (GSSG), its oxidized form. 29 The design of
the MMCNPs is such that once they are exposed to an intracellular GSH environment, the nanoprobes will break apart
into its different constituents that make up the composite
nanoprobes. This forms the basis of the intracellular tracking
of the STAT-3 drug release as schematically shown in FIG.
la. Distinct changes in absorption spectra were observed for
IONP-Qdot and IONP-Qdot-STAT3 conjugates in comparison to Qdots (FIG. 9). The Qdot absorption spectrum broadens significantly and slightly shifts towards longer wavelength when conjugated to IONPs. However, upon further
conjugation with NAC-STAT3 drug, NAC-FA and NACEDA, a decrease in spectral width along with slight blue shift
was observed with respect to the IONP-Qdots conjugates.
Such changes in absorption spectral characteristics support
successful surface conjugation of Qdots with IONP, STAT3
drug and FA. The emission of MMCNP is slightly blue shifted
compared to either Qdots or IONP-Qdot conjugates (FIG.
10).
Fluorescence data acquired by adding GSH to MMCNPs in
solution show that Qdot fluorescence can be substantially
restored in less than one hour (FIGS. 2a and 2b). Furthermore, a systematic study on the effect of GSH concentration
on the time scale of fluorescence restoration shows that there
is no significant effect of varying GSH concentrations in the
range of 2.8 mM to 7 mM (FIG. 11). The observed spectral
features of the "ON" state Qdots (i.e. after release from
MMCNP) (FIG. 2a) are in good agreement with those of
Qdots in solution as shown in FIG. 10. The STAT-3 inhibitor
is also a fluorescent molecule O'-ex: 300 nm and "-em: 396 nm)
of which the fluorescence is substantially quenched in MMCNPs. Fluorescence quenching of STAT-3 drug is presumably
due to electron/energy transfer from STAT-3 to Qdots. It is
unlikely that the IONP will have any significant contribution
towards STAT-3 fluorescence quenching as STAT-3 is not
directly attached to IONP surface. Restoration of STAT-3
drug emission is observed once MMCNPs are treated with
GSH in solution (FIG. 2b ), thus confirming disintegration of
MMCNPs and release of STAT-3 inhibitors.
To confirm the effectiveness of the optically activatable
nanoprobes (MMCNPs), the MMCNPs were challenged
against the intracellular GSH environment where the reported
GSH concentration is in the millimolar (mM) range, typically
between about 2 mM and about 15 mM27 •28 . The human
breast cancer (MDA-MB-231) cell line, known to over-express folate receptors 30 , and the mouse thymus stromal epithelial cell line (TE-71) were incubated forup to 24 hrs with
MMCNP at a concentration of about 50 µg/mL. As expected,
a significant uptake of folate conjugated MMCNPs by the
cancer cells was observed compared to normal cells as shown
in FIG. 3. These results also show that substantial restoration
of fluorescence occurs within 3 hr incubation. Restoration of
fluorescence in cancer cells is a direct confirmation of targeted cellular uptake of MMCNPs and subsequent dispersal
ofMMCNPs into its separate components, e.g., IONP, Qdots,
and the release of ligands, including drug molecules.
Systematic optical studies were performed to investigate
intracellular drug release at the single cell level. Confocal
microscopy images of the MDA-MB-231 cells incubated
with MMCNPs for 5 hrs (FIGS. 4a-4c) clearly show that
MMCNPs were uptaken by the cells. In addition, strong fluorescence signal from only a few locations in the cell can be
observed. These data show that Qdots were released from the
MMCNP through the cleavage of disulfide bonds by GSH
(see FIG. la). Besides the images of single cells incubated
with MMCNPs, emission spectra of different regions in
single cells were also collected (FIG. 4c, red and cyan lines).
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The Qdots in the intracellular environment show emission
spectra that are red-shifted and broadened with respect to
uncoated free Qdots in solution (FIG. 10). These spectral
differences are attributed to aggregation of the Qdots after
release from MMCNP in the cytosol. This observation was
confirmed with solution experiments on bare Qdots by
observing emission spectra before and after aggregation, as
well as addition of GSH to each of these samples (data not
shown).
It was found from control experiments that addition of
GSH to a suspension of bare Qdots leads to a stable Qdot
suspension and has no noticeable effect on the Qdot emission
properties (data not shown). These observations may provide
preliminary indication that in the intracellular environment
GSH does not necessarily exchange with the NAC/cargoligand that is initially present on the Qdot surface due to the
fact that intracellular Qdot aggregation is observed after
cargo release, although it could be argued that binding constants of both molecules could be comparable given that GSH
and NAC both contain a single thiol group in their structure
(monodentate ligand).
The observation of only a few bright spots in a single cell in
the fluorescence images indicates aggregation of multiple
Qdots in a single or a few clusters. The Qdot aggregation is
reasonable given that while in the MMCNP, Qdots are stabilized by PEG. After exposure to GSH, the PEG is removed by
cleavage of disulfide bonds, resulting in hydrophobic Qdots
that self-aggregate. In addition, the data shows that these
Qdot aggregates preferentially localize near the cell membrane, again due to their hydrophobic nature. Other locations
where Qdot aggregates are not present only show autofluorescence. It should be noted that while the STAT3 drug itself
is typically also fluorescent (FIG. 2b), experiments on intracellular delivery cannot be reliably performed by measuring
the STAT3 drug fluorescence due to weak fluorescence and
the presence of cellular auto-fluorescence, hence the need for
the optical signal of the Qdots.
To demonstrate the concept of multimodality of the MMCNPs, an agar phantom was prepared using a 10 mm NMR tube
(FIGS. Sa-Sd) for MRI and optical imaging studies. FIG. Sa
shows the schematic of agar phantom design. The bottom part
of the tube contains only MDA-MB-231 cells (as a control),
middle part contains only MMCNPs (as a control) and the top
part of the tube contains the same cells loaded with MMCNPs. All of these were dispersed in 3% agarose gel under
same condition. A digital image of the tube was recorded
under room light (FIG. Sb) as well as under illumination by a
hand-held 366 nm multiband UV lamp (FIG. Sc). The unfiltered images clearly show a light brown color where cells are
located in room light conditions whereas an intense red color
appears due to Qdot fluorescence under UV illumination. The
MDA-MB-231 cells loaded with theMMCNPs emit red fluorescence that is clearly visible to the naked eye. Control cells
do not show any detectable fluorescence emission. An MRI
image of the phantom (FIG. Sd) clearly shows cell clusters
that correlate well with the fluorescence image. A 3D reconstruction of the MR images is provided in FIG. 13. This
demonstrated the appearance of strong MRI signal from the
MDA-MB-231 cells loaded with the MMCNPs (indicated
with false red color) in contrast with the control cells.
A CyQUANT™ cell proliferation assay was used in a
comparative cell viability study to determine cytotoxicity of
MMCNPs without STAT-3 drug (control particle), STAT-3
drug itself, and MMCNPs with STAT-3 conjugation. Two
cancer cell lines, MDA-MB-231 and pancreatic (Pane- I) cancer cells were used along with mouse thymus stromal epithelial TE-71 cells (control). Results (shown in FIG. 6) suggest

that MMCNPs (with STAT-3) treated cancer cells have lower
viability than cells treated with free STAT-3 drug when
MMCNPs and STAT-3 were administered to the cell medium
at identical concentrations. This finding is highly significant
given that free STAT3 drug alone in medium is in high excess
compared to STAT-3 drug present in MMCNPs under these
conditions. Even though the MMCNPs consume much less
STAT3 drug, the delivery efficiency is dramatically increased,
thus resulting in increased therapeutic efficiency while minimizing the potential for medical side effects due to presence
of excess free drug.
In view of the above, a new and unique quantum dot
(Qdot)-iron oxide (IO) based multimodal/multifunctional
nanocomposite probe that is optically and magnetically
imageable, targetable and capable of reporting on intracellular drug release events has been described herein. By design,
the present nanoparticle system has multimodalities (optically and magnetically active) and multifunctionalities (i.e.
imaging, targeting, drug delivery) that are current state-ofthe-art in nanomedicine research 1 •8 •10 •14- 16 •18 •23 - 26 . In addition, the MMCNP discussed here integrate sensing modalities
that report on the event as well as the location ofintra-cellular
release of cargo (drug, etc.). The impact and implications of
this new development along with the traditional multimodalities and multifunctionalities are immediate for drug discovery and cancer biology.
In accordance with another aspect, there is provided a
method for monitoring intracellular drug delivery within a
subject using any embodiment of an optically activatable
nanoprobe described herein. In one embodiment, the method
comprises administering to the subject an effective amount of
a nanoprobe comprising an inorganic core and a plurality of
quantum dots linked to the inorganic core. A ligand comprising at least an active agent is linked to respective ones of the
plurality of quantum dots. Upon intracellular uptake of the
nanoprobe, the linkage between the active agent and the
ligand is cleaved to allow release of the active agent and to
allow the plurality of quantum dots to transfer from a
quenched state, wherein the luminescence of the plurality of
quantum dots is quenched, to a luminescent state, wherein the
luminescence of the plurality of quantum dot is activated. In
one embodiment, the linkage between the bioactive agent and
the quantum dot is cleavable by intracellular glutathione
(GSH).
In a particular embodiment, the ligand may further comprise a targeting agent and a hydrophilic dispersing agent. For
example, the active agent may comprise a STAT3 inhibitor,
the targeting agent may comprise folate, and the hydrophilic
dispersing agent may comprise m-polyethylene glycol
(mPEG) or derivatives thereof. In addition, optionally, the
bioactive agent, targeting agent, and the hydrophilic dispersing agent may be modified with N-Acetyl-L-Cysteine to provide improved dispersability of the nanoprobes and additional functional groups for the attachment of desired ligands.
In addition, the above-described method may further comprise the step of detecting a presence of the plurality of quantum dots, wherein an increase in luminescence of the quantum dots is indicative of a release of the active agent
intracellularly. The detecting may be done by any suitable
detection method known in the art appropriate for the particular type of Qdot. For example, the detection may be done by
any one or more of transmission electron microscopy (TEM),
scanning electron microscopy (SEM), dynamic light scattering (DLS), UV-visible (UV-VIS) spectroscopy, Fouriertransform infrared spectroscopy (FTIR), zeta potential, high pressure liquid chromatography-mass spectrometry (HPLC-MS),
NMR/IR, mass spectrometry (MS), fluorescence excitation
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and em1ss10n spectroscopy and fluorescence microscopy,
near infrared (NIR) imaging (NIRS), and magnetic resonance
(MR) imaging and spectroscopy
The administering to the subject, who may be any mammalian subject, may be done according to any suitable route
of in vivo administration that is suitable for delivering the
composition into the subject. The preferred routes of administration will be apparent to those of skill in the art, depending
on the medium, the targeting agent (if present) or the active
agent. Exemplary methods of in vivo administration include,
but are not limited to, intravenous administration, intraperitoneal administration, intramuscular administration, intranodal administration, intracoronary administration, intraarterial administration (e.g., into a carotid artery), subcutaneous
administration, transdermal delivery, intratracheal administration, intraarticular administration, intraventricular administration, inhalation (e.g., aerosol), intracranial, intraspinal,
intraocular, intranasal, oral, bronchial, rectal, topical, vaginal, urethral, pulmonary administration, impregnation of a
catheter, and direct injection into a tissue.
In accordance with another aspect, there is provided a
method for making optically activatable nanoprobes as
described herein. The method comprises obtaining a plurality
of nanoparticles comprising an inorganic core, e.g., iron
oxide core; obtaining a plurality of quantum dots; linking the
plurality of quantum dots to the inorganic core; and linking at
least one ligand to respective ones of the plurality of quantum
dots, wherein the at least one ligand comprises an active
agent, a targeting agent, or a hydrophilic dispersing agent. In
a particular embodiment, the at least one ligand comprises an
active agent, a targeting agent, and a hydrophilic dispersing
agent. As discussed above, the active agent may comprise a
STAT-3 inhibitor, the targeting agent comprises folate, and
the hydrophilic dispersing agent comprises polyethylene glycol (e.g., mPEG).
Further, in one embodiment, the method further comprises
providing a coating of dihydrolipoic acid (DHLA) about the
inorganic core to connect/link the Qdots to the iron oxide
core. In some embodiments, the method further comprises
modifying at least one of the active agent, the targeting agent,
and the hydrophilic dispersing agent with N-Acetyl-L-Cysteine to increase dispersability and multifunctionality of the
nanoprobe. A specific process for making optically activatable nanoprobes as described herein is set forth in the
example below.
In accordance with another aspect of the present invention,
there is provided another embodiment of a multi-modal,
multi-functional nanoparticle (hereinafter DNCP or DNCPs)
that allows for enhanced in vivo efficacy of active agents, as
well as allows for the improved non-invasive in vivo bioimaging. In one embodiment, the DNCPs comprise an optically activatable nanoprobe having a core component. In this
embodiment, the core component comprises a quantum dot
core and at least one ligand linked to the quantum dot core. In
this embodiment, the DNCPs differ from the above-described
nanoparticles in that the Qdot itself comprises the nanoparticles' core rather in contrast to the inorganic core described
above having a plurality of satellite Qdots surround an inorganic core. A number of different chemical entities may be
linked to the DNCPs, such as active agents, imaging agents,
and targeting agents according to the same structures and
methods described above.
In one embodiment, at least one active agent, e.g., a NACmodified STAT3 inhibitor, is linked to the Qdot core by a
disulfide bond, for example. In this way, when the STAT3
inhibitor is linked to the Qdot core, the STAT3 drug attachment to the Qdot surface will substantially quench Qdot fluo-

rescence. The restoration of Qdot fluorescence will take place
when intracellular GSH acts upon the DCNP, cleaving the
disulfide bond and releasing STAT3 drug from the DNCP
core into the cytosol. Restoration of fluorescence typically
involves at least a noticeable increase of fluorescence from a
substantially quenched state.
In one embodiment, a chitosan-based shell surrounds the
Qdot core and any chemical entities attached thereto in the
DCNPs. In one embodiment, the chitosan-based shell comprises a chitosan polymer and a hydrophilic dispersing agent.
Chains of the chitosan polymer electrostatically interact with
chains of the hydrophilic dispersing agent to form an
entangled network comprising the chitosan polymer and the
hydrophilic dispersing agent. While not wishing to be bound
by theory, it is believed that the chitosan-based shell will
effectively scavenge ion leakage, e.g., cadmium ion leakage,
from the Qdot core by forming a metal-ligand complex and
will passivate cytotoxicity. When a plurality of active agents
(e.g., a STAT-3 inhibitor) are attached to the Qdot core, the
plurality of active agents may be released intracellularly upon
cleavage of the bond between the active agents and the Qdot
core.
The hydrophilic dispersing agent of the chitosan-based
shell may be any compound having repeating structural units
that have one or more functional groups that will interact by
electrostatic or charge attraction (or otherwise) with the
amine functional groups of the chitosan polymer. In one
embodiment, the hydrophilic dispersing agent is a polymer
other than chitosan having repeating structural units, wherein
each of the structural units includes one or more carboxyl
groups. In a particular embodiment, the hydrophilic dispersing agent comprises polyglutamic acid (PGA) or any structural analogues or derivatives thereof. The advantages of utilizing PGA as the hydrophilic dispersing agent include the
fact that PGA is a negatively charged biocompatible and
biodegradable natural polymer, rendering it suitable for in
vivo applications. Similarly, PGA increases the overall
hydrophilicity of the chitosan-based nanoparticles, thus
improving the stability of the nanoparticles having PGA
therein at physiological pH conditions (e.g., pH 7.4). Further,
PGA provides additional functional groups to incorporate
additional functionality and/or modalities to the nanoparticles, such as the attachment of imaging agents, targeting
agents, and/or further active agents to the nanoparticles. Even
further, the incorporation of PGA in the nanoparticles will
reduce the positive surface charge on each of the nanoparticle's surface (relative to a chitosan-based nanoparticle without the PGA), which will likely aid in reducing non-specific
uptake by cells.
Alternatively, the hydrophilic dispersing agent may comprise or further comprise any other compound that will
increase the hydrophilicity of the DNCPs relative to a nanoparticle without the hydrophilic dispersing agent. In other
embodiments, for example, the hydrophilic dispersing agent
may comprise one or more ofNAC, glutathione, PEG (polyethylene glycol), m-PEG, PPG (polypropylene glycol),
m-PPG, polysialic acid, polyaspartate, polylysine, polyethyeleneimine, biodegradable polymers (e.g., polylactide,
polyglyceride ), and functionalized PEG, e.g., terminal-functionalized PEG, analogues, derivatives, or combinations
thereof of the above compounds. Optionally, a cross-linking
compound may be provided to conjugate the amine groups of
the chitosan polymer and the carboxyl groups of the hydrophilic dispersing agent together.
The at least one ligand linked to the Qdot may comprise an
active agent, a targeting agent, a hydrophilic dispersing agent,
an imaging agent, any other desired compound, and combi-
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nations thereof. In one embodiment, the biologically active
agent, targeting agent, and/or imaging agent are linked to the
Qdot core via thiol groups on the Qdot surface. In another
embodiment, the biologically active agent, targeting agent
and/or imaging agent may be linked to the chitosan-based
shell, e.g., to either or both of the chitosan polymer and the
hydrophilic dispersing agent. It is contemplated that the additional ligands described herein may be linked to the chitosan
polymer by bonding, covalent or otherwise, through the
amine groups of the chitosan polymer, although the invention
is not so limited. When the chitosan-based shell comprises
PGA, the respective ligand may be bonded to the hydrophilic
dispersing agent through compatible functional groups on the
hydrophilic dispersing agent. For example, when the hydrophilic dispersing agent is PGA, the additional ligand may be
bonded to the PGA polymer through its amine or carboxyl
functional groups. In some embodiments, spacer molecules
or coupling agents may be utilized between the ligand to be
attached and the chitosan polymer or the hydrophilic dispersing agent to provide the linkage between the ligand and the
other substrate.
The active agent, imaging agent, hydrophobic dispersing
agent, and the targeting agent may be any compound as
described or defined herein. Further, in any embodiment, the
active agent, imaging agent, hydrophobic dispersing agent,
and the targeting agent may be activatable as define herein. In
one embodiment, the active agent is a STAT3 inhibitor, such
as one or more of BP-1-102, SF-1066 and S31-201, all of
which have proven activity against STAT3 with IC 50 values of
6.8, 35, and 86 µm, respectively. FIG. 15 shows the structure
ofBP-1-102, for example. As mentioned above, the STAT3
inhibitor may be NAC-modified. FIG. 16 illustrates an exemplary NAC-modified STAT3 inhibitor.
The imaging agent may comprise one or more of a fluorophore, iohexy1, and a paramagnetic chelate having a paramagnetic ion bound therein. In one embodiment, either or both of
the hydrophilic dispersing agent and the chitosan polymer
may be labeled with a fluorophore. In another embodiment,
either or both of the hydrophilic dispersing agent and the
chitosan polymer may be labeled with a fluorophore and also
a paramagnetic chelate (chelator) having an MRI (magnetic
resonance imaging) contrast agent bound therein linked to the
chitosan polymer so that the recovered stabilized chitosanbased nanoparticles are effective as a bimodal agent that is
fluorescent as well as paramagnetic. The MRI contrast agent
may comprise a paramagnetic ion selected from one or more
of gadolinium, dysprosium, europium, and compounds, or
combinations thereof, for example. In one embodiment, the
paramagnetic ion comprises a gadolinium ion and the chelator is a DOTA-NHS ester (2,2',2"-(10-(2-(2.5-dioxopyrrolidin-1-yloxy )-2-oxoethyl)-14, 7, 1O-tetraazacyclododecane-1,
4,7-tryl)triaceticacid). Gd3 + ions are paramagnetic and
DOTA is a chelator of Gd ion. The Gd-DOTA is paramagnetic
agent and it provides MRI contrast. Gd-DOTA is commercially available under the brandname ProHance® (also called
Gadoteridol). In another embodiment, either or both of the
chitosan polymer or the hydrophilic dispersing agent may be
solely or additionally linked with iohexyl such that the recovered nanoparticles are radio-opaque.
A particular embodiment of a DNCP having a Qdot core
and a chitosan-based shell is shown in FIG. 14. It is appreciated that the illustrated embodiment is merely exemplary and
that the nanoparticles may include more or less chemical
entities than shown, or may comprise entirely different
chemical entities. In the illustrated embodiment, the DNCP
comprises a Qdot core, which may be any quantum dot material as described above, such as CdS:Mn/ZnS or ZnS:Mn/

ZnS. To the Qdot surface, there is attached a N-acetylcysteine
(NAC)-modified STAT-3 inhibitor. N-acetylcysteine acts a
Qdot surface passivator, as well as a linker between the
STAT-3 inhibitor and the Qdot core through its carboxyl
and/or thiol groups.
The chitosan-based shell comprises chitosan polymer
(commercially available; had a measured molecular
weight=approximately 5.3x105 Da; a degree of acetylation=77) and PGA (commercially available, MW approximately 4130 Da, biocompatible/biodegradable). The chitosan
polymer includes a plurality of amine groups, which will
interact by electrostatic or charge attraction (or otherwise)
with the carboxyl groups of the PGA to form an entangled
network of the two polymers. In the embodiment shown, the
PGA and chitosan polymer are cross-linked using a watersoluble carbodiimide cross-linker (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) (EDC). Alternatively, any other
cross-linking compound may be utilized. EDC coupling conjugates the amine groups of the chitosan polymer and the
carboxyl groups of the PGA together forming an amide bond.
In the illustrated embodiment of FIG. 14, two imaging
agents (Alexa Fluor® 660 and Gd-DOTA) are bonded to the
chitosan polymer. Alexa Fluor® 660 is a commercially available, amine-reactive, near infrared (NIR)-emitting fluorescent dye (MW approximately 1300; wavelength of absorption
and emission band maxima are 663 nm and 690 nm, respectively; molar extinction coefficient 132,000 cm-1 M-1). GdDOTA is a commercially available amine-reactive paramagnetic Gd-chelate complex, which is typically used as a MRI
Tl contrast agent. In addition, to the chitosan polymer, there
is bonded a folate targeting agent having both amine and
carboxyl functional groups.
In one embodiment, the DNCPs of FIG. 14 may be synthesized by forming three different W/0 microemulsions (ME-I,
ME-II and ME-III). Each microemulsion comprises an oil, a
surfactant, and an aqueous phase having a chitosan polymer.
Each microemulsion, however, includes a different aqueous
phase. The ME-1 aqueous phase comprises Qdots, NACconjugated STAT-3 inhibitor (NAC-Drug) and chitosan polymer. The aqueous phase of ME-II will contain two components, Alexa Fluor® 660 NIR dye conjugated to chitosan
polymer (chitosan-dye) and DOTA-Gd (III) conjugated-chitosan polymer (chitosan-DOTA-Gd). The ME-III aqueous
phase will contain EDC cross-linker and folate-conjugated
PGA (PGA-folate) and PGA polymer. In an exemplary
embodiment, an ME composition contains 6.0 mL Triton
X-100 (neat), cyclohexane (11.0 mL), n-hexanol (4 mL), and
4.0 mL water (i.e. aqueous phase). It is noted that ME-I,
ME-II and ME-III vary with respect to their aqueous phase
contents.
The surfactant may be any suitable surfactant known in the
art. In particular embodiments, the surfactant comprises a
non-ionic surfactant, such as Triton X-100 (e.g., an octylphenol ethylene oxide condensate (P-octyl polyethylene glycol
phenyl ether)), available from Union Carbide, USA. Alternatively, the surfactant may be any other suitable surfactant
material, such as a fatty acid ester, a polyglycerol compound,
a polyoxyethylene surfactant, e.g., asBrij-30, Brij-35, Brij92, Tween-20, and/or Tween-80.
In one embodiment, the microemulsions may also comprise a co-surfactant. In a particular embodiment, the cosurfactant comprises n-hexanol. N-hexanol is believed to stabilize the interface between oil and water along with the
primary surfactant. In another embodiment, the co-surfactant
comprises sodium bis(2-ethylhexyl) sulfosuccinate (docusate sodium), also sold commercially as Aerosol® OT (AOT).
The oil may be any hydrophobic compound, such as one that
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is immiscible with water, e.g., aliphatic and aromatic hydrocarbons.Non-limiting examples of suitable oils for use in the
present invention, e.g. in the first and second microemulsions,
include aliphatic and aromatic hydrocarbons, e.g., hexane,
heptane, cyclohexane, toluene and benzene. In a particular
embodiment, the oil comprises cyclohexane. The water
(aqueous phase) to surfactant molar ratio may be any suitable
ratio appropriate for the particular materials and application,
such as from about 2:1 to about 70:1, and in a particular
embodiment about 22: 1.
To form the DCNPs, ME-II was added to ME-1 followed
by addition of ME-III to the mixture. In ME-I, Qdots will be
covalently conjugated to NAC-Drug and the resulting conjugate will be coated with chitosan polymer (DNCP core). The
ME-II aqueous components will further coat Qdots and protect drugs. EDC will cross-link chitosan and PGA polymers,
forming a stable polymeric shell (DNCP shell). Due to the
confined environment of the water droplets, the resulting
DCNP size is expected to be about 30 nm.
The produced DNCPs may offer one or more of the following advantages: (i) imageable by both MRI and NIR
modalities; (ii) targetable to tumor cells over-expressing
folatereceptors; (iii) therapeutic as it carries Stat3 SMI (small
molecule inhibitor drugs); (iv) particles are highly hydrophilic and stable in phosphate buffer due to their hybrid nature
(chitosan-PGA); (v) biocompatible and stable (cross-linked)
DNCP shell structure (biodegradation rate is expected to be
quite slow due to cross-linking); (vi) non-heavy metal based
DNCP core when non-cadmium based ZnS:Mn/ZnS core is
selected; (vii) Improved FRET performance is expected for
CdS:Mn/ZnS Qdots over ZnS:Mn/ZnS Qdots (as CdS:Mn/
ZnS Qdots is excited efficiently at longer wavelength); (viii)
DNCP with CdS:Mn/ZnS core may not exhibit cytotoxicity
as the core is well protected by the cross-linked DNCP shell;
and (ix) hundreds ofSMis (small molecule inhibitors) will be
captured in a single particle and they will remain protected
from the adverse extra-cellular environment.
The DNCPs are also porous and hydrophilic particles.
When the particles are administered to a subject, and thereafter internalized and exposed to the cytosolic glutathione
(GSH) environment, the disulfide bond between the active
agent and the Qdot may be cleaved by GSH, resulting in the
release of the active agent. The rate of release of the active
agent will depend on several factors, including the diffusion
rate of glutathione, concentration of intra-cellular glutathione, interaction of drug to polymeric shell, and the like.
It is highly feasible to establish a sustained drug release
mechanism by controlling the thickness of the DNCP shell
and degree of cross-linking.
The Qdot fluorescence in the DNCP will be quenched due
to an electron transfer process between the nanoparticles'
Qdot core and the Qdot's ligands, e.g., active agents. The
restoration of Qdot emission will occur once drugs are
released from Qdot surface upon interaction with intra-cellular glutathione. In one embodiment, the Qdot and the Alexa
Fluor® 660 are present together in the same nanoparticle and
are purposely selected to form a FRET pair where the Qdot
will serve as a donor (600 nm emission) and the Alexa Fluor®
660 (663 nm excitation and 690 nm emission maxima) will
serve as an acceptor. In absence of glutathione, Qdot emission
is in the "OFF" state, but Alexa Fluor® emission is in the
"ON" state when excited at 663 nm (therefore, trackable by
NIR imaging in vivo). The quantification of drug release, for
example, may be based on a FRET scheme with Qdot core as
the donor and the Alexa Fluor® NIR dye as the acceptor under
Qdot excitation. The ratio of emission intensity of Alexa
Fluor® 660 (measured at 690 nm) to Qdot (measured at 600

nm) may be directly correlated to the total amount of drugs
present in DNCPs (actual concentration of drugs can be quantified by treating DNCPs with excess amount glutathione and
measuring drug fluorescence).
It is appreciated that measure of emission intensities at
Alexa Fluor® 660 and Qdot peak emission wavelengths is
expected to be appropriate to minimize spectral cross-talk
while maximizing signal to background ratio. The ratio of
emission intensity of Alexa Fluor® to Odot will likely
increase drastically once drug is released from the DNCPs
and FRET occurs from Qdots to Alexa Fluor®. It is noted that
only drug molecules are expected to escape from the DNCP
and both Qdot and Alexa Fluor® 660 will remain integrated
within the particle in the chitosan-based shell. The amount of
drug release can be quantified in solution experiments, for
example, by constructing a calibration curve of the above
intensity ratio versus drug concentration. This calibration
curve can be used to estimate drug release in vivo (semiquantitatively).
As set forth in Table 1 below, several characterization techniques may be utilized to evaluate DNCPs. Without limitation, these techniques include transmission electron microscopy (TEM), scanning electron microscopy (SEM), dynamic
light scattering (DLS), UV-visible (UV-VIS) spectroscopy,
Fourier transform infrared spectroscopy (FTIR), zeta potential, high pressure liquid chromatography-mass spectrometry
(HPLC-MS), NMR/IR, mass spectrometry, fluorescence
excitation and emission spectroscopy and fluorescence
microscopy, near infrared (NIR) imaging (NIRS), and magnetic resonance (MR) imaging and spectroscopy. Exemplary
uses for each technique with respect to the nanoprobes
described herein are set forth in Table 1 below.
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Tests
1. Fluorescence
(excitation and
emission)
40 spectroscopy
2. Fluorescence
Confocal
microscopy
3. Electron
45 microscopy
(transmission/
scanning)
4. Dynamic light
scattering
50
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5. Zeta Potential
Measurement
6. UV-VIS
measurement
7. NMR/IR
spectroscopy
8. FTIR
9. HPLC-MS
10. Mass Spec
11. NIR Imaging

60 12. MR imaging
and spectroscopy
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Purposes
1. To perform systematic photophysical
characterization ofDNCP at different stages of
development including characterization of drug
loading and release
2. To perform microscopic imaging ofDNCP
internalized cancer cells to investigate
localization of particles and their fate in
intracellular environment
3. To evaluate DNCP size and morphology

4. To evaluate DNCP size distribution and to
study their state of dispersion in phosphate
buffer.
5. To evaluate DNCP surface charge
6. To characterize absorption ofDNCP

7. To characterize Stat3 inhibitor,
Qdot-NAC-Stat 3 conjugate, EDC based covalent
coupling (cross-linking)
8. To characterize chemical structure using
infrared (IR) spectroscopy
9. To characterize drug loading
10. To characterize Stat3 inhibitor construct
11. To perform optical based in vivo tumor
imaging at NIR region
12. To determine Tl, T2 and T2* for agar
phantom embedded with DNCP loaded cancer
cells as well as tumor tissue

The present inventors have undertaken a successful synthestis ofDNCP that comprise Qdot-STAT3 small molecule
inhibitor (SMI) conjugates and have observed Qdot fluorescence quenching, SMI fluorescence quenching, Qdot and
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STAT3 restoration upon treatment with glutathione, and
folate receptor-mediated specific uptake as with the MMCNPs set forth above. Further, the present inventors have
observed Qdot fluorescence restoration of the DCNPs in
MDA-MB-231 cells upon interaction with the intra-cellular
glutathione. A few exemplary benefits and uses of the DNCPs
are further summarized in Table 2 below.

Phospholipids preferably form an important part of liposomes. Phospholipids are, in their simplest form, composed
of glycerol bonded to two fatty acids and a phosphate group.
The resulting compound called phosphatidic acid contains a
region (the fatty acid component) that is fat-soluble along
with a region (the charged phosphate group) that is watersoluble. Most phospholipids also have an additional chemical
group bound to the phosphate. For example, ifthe phosphate
is connected with choline; the resulting phospholipid is called
phosphatidylcholine, or lecithin. Other phospholipids
include phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine. The fatsoluble portions associate with the fat-soluble portions of
other phospholipids while the water-soluble regions remain
exposed to the surrounding solvent. The phospholipids of the
cell membrane form into a sheet two molecules thick with the
fat-soluble portions inside shielded on both sides by the
water-soluble portions. This stable structure provides the cell
membrane with its integrity.
The components ofliposomes determine the physical characteristics of the liposome. Liposomes preferably consist of
amphipathic lipid molecules, with phospholipids being the
major component. Most commonly, phosphatidylcholine is
used as the primary constituent. Other lipids, including phosphatidylethanolamine, phosphatidylserine, sphingomyelin,
glycolipids and sterols are often added. The physical characteristics ofliposomes depend on pH, ionic strength and phase
transition temperatures. The phase transition consists of a
closely packed, ordered structure, called as the gel-state, to a
loosely packed, less-ordered structure, known as the fluid
state. The phase transition temperature (Tc) depends on the
acyl chain length, degree of saturation, and polar head group.
For example, the Tc of egg phosphatidylcholine with a high
degree of unsaturation of the acyl chains and varying chain
length is -15 degrees C. However, in a fully saturated distearoylphosphatidylcholine (DSPC), Tc is over 50 degrees C.
Most liposomal formulations contain cholesterol in order to
form a more closely packed bilayer system during preparation. Cholesterol addition to phosphatidylcholine changes the
melting behavior of the bilayer, as cholesterol tends to eliminate the phase transition. Cholesterol addition has a condensing effect on the fluid-state bilayer and strongly reduces
bilayer permeability.
The fusion of lipid vesicles has been demonstrated to be a
powerful approach to create a continuous and fluid lipid
membrane on planar solid substrates. (Sackmann, E., Supported Membranes: Scientific and Practical Applications.
Science 1996, 271, 43.) Recently, there are several reports on
the formation of lipid bilayers on nanoparticles by the fusion
of small unilamellar vesicles. (e.g., Cauda, V.; Engelke, H.;
Sauer, A.; Arcizet, D.; Brauchle, C.; Radler, J.; Bein, T.,
Colchicine-Loaded Lipid Bilayer-Coated 50 Nm Mesoporous Nanoparticles Efficiently Induce Microtubule Depolymerization Upon Cell Uptake. Nano Letters 10, 2484; Li, P.
C.; Li, D.; Zhang, L. X.; Li, G. P.; Wang, E. K., Cationic Lipid
Bilayer Coated Gold Nanoparticles-Mediated Transfection
ofManimalian Cells. Biomaterials 2008, 29, 3617; or Mornet, S.; Lambert, O.; Duguet, E.; Brisson, A., The Formation
of Supported Lipid Bilayers on Silica Nanoparticles Revealed
by Cryoelectron Microscopy. Nano Letters 2005, 5, 281) It
has been shown that the structure of nanoparticle-supported
lipid bilayers is similar to that formed on planar substrates.
The coating oflipid bilayers include the enhancement of the
circulation time, accumulation of nanoparticles in cells and
the minimization of the toxicity ofnanoparticles.
In a specific embodiment, the invention pertains to a
method of producing a nanoprobe encased in a lipid vesicle.

TABLE2
Objectives

Approach

i) Specific delivery
of anticancer drugs
to tumor cells
ii) Promoting drug
stability
iii) Tracking drugs
in vivo
iv) Confirmation of
drug release in
vivo

i) Via folate-receptor mediated targeting

v) Quantification of
drug concentration
within tumor tissue
vi) Monitor tumor
size
vii) Track tumor
cells

viii) Monitor tumor
metastasis

ii) By encapsulating drugs within DNCP core
iii) By MRI (Gd-DOTA) and NIR (Alexa Fluor 660)
imaging ofDNCP
iv) Drug conjugated Qdots are in fluorescently
quenched ("OFF") state due to
electron/energy transfer process. Drug release
process will restore Qdot fluorescence
("ON" state). The "ON" state
Qdot will tum on NIR emission of Alexa Fluor
through fluorescence resonance energy transfer
(FRET) process.
v) By measuring ratio of fluorescence
intensity of Alexa Fluor (at 690 nm)
to Qdot (at 600 nm). The ratio will increase
with the release of drugs from DNCP.
vi) by measuring volume of MRI as well as
NIR 3D image contrast volume)
vii) By MRI and NIR imaging. High Tl
relaxivity ofDNCP is the key and tracking
of a few tumor cells together is feasible.
Bright NIR emission from Alexa Fluor will
minimize tissue scattering and
auto-fluorescence, thus improving optical
imaging sensitivity down to a cluster of
tumor cells.
viii) Again by MRI and NIR imaging. Due to
high MRI and optical sensitivity of the
DNCP, imaging of metastatic twnor cells is
highly feasible. For monitoring tumor
metastasis over a period of time, multiple
administration ofDCNP buffer formulation
will be required.

According to another embodiment, the invention pertains
to a nanoprobe comprising an inorganic core or an inorganic/
Qdot hybrid core. Either of these core components are associated with an activatable active agent. In one embodiment,
the active agent is one that will be released from the core upon
exposure to an endogenous molecule, such as glutathione.
The nanoprobe is also at least partially or fully encased in a
lipid vesicle. In a more specific embodiment, the lipid vesicle
is functionalized to promote cellular uptake. Non-limiting
examples of functionalization, e.g., surface functionalization,
is the linkage of folic acid and/or TAT-peptide to the lipid
vesicle.
A non-limiting list of other phospholipids that may be used
to form lipid vesicles includes but is not limited to, one or
more of hydrogenated soy phosphatidylcholine (HSPC), egg
phosphatidylcholine (EPC), phosphatidylethanolamine (PE),
phosphatidylglycerol (PG), phosphatidylinsitol (PI), monosialogangolioside, spingomyelin (SPM), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylcholine
(DMPC), or dimyristoylphosphatidylglycerol (DM PG). In
certain embodiments of the invention, the ratio of pharmaceutical agent to lipid-protein ranges from about 0.0005 to
about 1 (w/w), more preferably about 0.0005 to about 0.5
(w/w), more preferably about 0.001 to about 0.1 (w/w).
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In a more specific embodiment, CdS:Mn/ZnS Qdots are synthesized in a modular fashion following three steps.
In a first step, unmodified (bare) Qdots are synthesized
using a dioctyl sulfosuccinate sodium salt (AOT)/heptane/
water microemulsion system as described in the literature.
(Santra, S.; Yang, H. S.; Holloway, P. H.; Stanley, J. T.;
Mericle, R. A., Synthesis of Water-Dispersible Fluorescent,
Radio-Opaque, and Paramagnetic Cds: Mn/Zns Quantum
Dots: A Multifunctional Probe for Bioimaging. Journal ofthe
American Chemical Society 2005, 127, 1656; Santra, S.;
Yang, H.; Dutta, D.; Stanley, J. T.; Holloway, P. H.; Tan, W.
H.; Moudgil, B. M.; Mericle, R. A., Tat Conjugated, Fite
Doped Silica Nanoparticles for Bioimaging Applications.
Chemical Communications 2004, 2810)
In a second step, S3I drug (containing a secondary nonfunctional amine group) will be chemically linked to NAC
using standard EDC (1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide, water soluble) coupling chemistry (as
described in reference (Santra, S.; Liesenfeld, B.; Dutta, D.;
Chatel, D.; Batich, C. D.; Tan, W. H.; Moudgil, B. M.;
Mericle, R. A., Folate Conjugated Fluorescent Silica Nanoparticles for Labeling Neoplastic Cells. Journal of Nanoscience and Nanotechnology 2005, 5, 899)) to obtain the
NAC-S3I conjugate. A 1:1 molar ratio ofNAC:S3I may be
used to avoid the presence of excess NAC in the reaction
mixture. In a previous paper, small lipid vesicles of Zwitterionic 1,2-bis(tricosa-10, 12-diynoy1)-sn-glycero-3-phosphocholine (DC8,9PC) were synthesized by dissolving lipid molecules in water at a concentration of 2 mg/mL. The lipid
solution was incubated at 50 degrees C. for 3 hours and then
extruded 10 times through a Nucleopore membrane using a
Lipex extruder. FIG. l9a shows an AFM image of resulting
vesicles.
Lastly, the NAC-S3I conjugate is reacted with the unmodified Qdots to obtain S3I surface conjugated Qdots. The product, Qdot-S3I conjugates, may be separated from the microemulsion system by thorough washing with 95% ethanol.
These particles are then be further surface modified with a
lipid bilayer (LB) to obtain LB coated QDot-S3I. Upon reaction with intracellular GSH, the disulfide bond between the
QDot core and NAC-S3I construct is cleaved, thus releasing
the drug from the QDot surface and resulting in restoration of
quenched Qdot fluorescence in proportion to amount of drug
released, as schematically illustrated in FIG. 17.
As described above, the nanorpobes may be coated with
lipid bilayers through the fusion of small unilamellarvesicles.
In a specific embodiment, Zwitterionic lipid (DC8,9PC),
positively charged lipid 1,2-dioleoyl-3-rimethylammoniumpropane (DOTAP) (FIG. 19b), and l-hexadecanoly,2-(9Z,
12Z-octadecadienoyl)-sn-glycero-3-phosphatidylethanolamine (PtdEtn) (FIG. 19c) is used. First, small unilamellar
vesicles ofDC8,9PC, DOTAP and PtdEtn with diameters in
the range of 15-50 nm are prepared by extrusion of hydrated
lipid films through filters with a pore size at the nanometer
scale with standard protocols. (Mayer, L. D.; Hope, M. J.;
Cullis, P. R., Vesicles ofVariable Sizes Produced by a Rapid
Extrusion Procedure. Biochimica Et Biophysica Acta 1986,
858, 161). The lipid bilayers obtained from PtdEtn or
DOTAP/PtdEtn mixtures can be further modified with folic
acid or TAT-peptide by covalently linking to the amine group
of PtdEtn. Second, the zeta potential of lipid bilayer-coated
Qdots is measured and small unilamellar vesicles to confirm
the fusion on Qdots. Third, the formation oflipid bilayers on
QDots is observed with cryotransmission electron microscope, which has been used in imaging the lipid bilayers on
silica nanoparticles. (Liu, J. W.; Jiang, X. M.; Ashley, C.;
Brinker, C. J., Electrostatically Mediated Liposome Fusion

and Lipid Exchange with a Nanoparticle-Supported Bilayer
for Control of Surface Charge, Drug Containment, and Delivery. Journal of the American Chemical Society 2009, 131,
7567). The resulting biosensor particles are shown in FIGS.
l8a-b. In particular, FIGS. l8a-b shows a nanoparticle 10
having a CdS:Mn/ZnS quantum dot core 12, to which an S3I
inhibitor drug 14 will be covalently linked via a cleavable
disulfide bond linkage. (a) a lipid bilayer 16 may be overcoated on the surface of the S3I conjugated CdS:Mn/ZnS
quantum dots. (b) the lipid bilayer may be further functionalized with folic acid 18 as shown in FIG. l8b to target cancer
cells that overexpress folate receptors, or with TAT peptide (a
cellpenetrating peptide).
In an alternative embodiment, the invention pertains to an
activatable nanoprobe. The nanoprobe embodiment comprises a core component that is associated with an active
agent. The core component may comprise an inorganic core
component. Alternatively, the core component may comprise
an inorganic/Qdot hybrid core. The active agent may be associated with a linker comprising a double sulfide bond. The
construction of the nanoprobe allows for activation of the
active agent when exposed to an endogenous compound such
as GSH. Thus, certain nanoprobe embodiments do not necessarily incorporate the use of a Qdot or similar optically
detectable means or structure.
The nanoprobes, ligands and compounds described herein
may be provided in an effective amount, namely an amount
effective to achieve the desired result.
The following examples are intended for the purpose of
illustration of the present invention. However, the scope of the
present invention should be defined as the claims appended
hereto, and the following examples should not be construed as
in any way limiting the scope of the present invention.
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EXAMPLE 1
The following example more particularly describes the
production of an exemplary quantum dot (Qdot)-iron oxide
(I 0) based multimodal/multifunctional nanocomposite pro be
(MMCNP) that is optically and magnetically imageable, targetable, and capable of reporting on intracellular drug release
events.
1.1 Materials
All the chemicals were used as received. Ferric (III) chloridehexahydrate, Ferrous (II) chloridetetrahydrate, ethylenediamine were purchased from Fluka. Lipoic acid and sodium
borohydride were purchased from Sigma-Aldrich. MethylPEG-12-NHS, and folic acid were purchased from Fisher
Scientific, USA. All the other chemicals and solvents were
also purchased from Fisher Scientific, USA. Nanopure water
(deionized and filtered water) was used for the following
example. Fluorescence spectra were recorded in NanoLog
Spec Fluorimeter, Perkin Elmer. The FTIR spectra were
recorded in a Perkin Elmer Spectrum 100. UV-Vis spectra
were recorded in a Cary Win UV spectrometer. The low and
high resolution electron microscopic images were taken in
TEM JEOL 1011 and FEI Tecnai F30 TEM instruments
respectively.
The STAT-3 inhibitor used was an SF-1-046 drug. The
non-phosphorylated salicylic acid-based small-molecule,
SF-1-046, belongs to the S3I-201.1066 class of STAT3
inhibitors 31 •32 . Compounds in this class, including SF-1-046,
are structural analogs of the previously reported lead STAT-3
dimerization disruptor, S3I-201 33 . Consistent with the published reports regarding the activities of the lead and the other
members of the second generation class of compounds 31 - 33 ,
GOLD computational modeling 34 indicated SF-1-046 inter-
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acts with the STAT3 SH2 domain (data not shown), disrupting
STAT3 SH2 domain:pTyr interactions, and thereby inhibits
STAT-3 activation. SF-1-046 was prepared via previously
published synthetic protocols 31 •32 .
1.2 Methods (Synthesis and Surface Modification of Iron
Oxide Nanoparticle Cores (IONPs) by Dihydrolipoic Acid)
Super paramagnetic iron oxide nanoparticles (IONPs)
were prepared following a previously established protocol 35 .
In brief, 1.0 M (1.13 g) of ferric chloride hexahydrate
(FeCl 3 .6H 2 0); 0.5 M (0.415 g) ferrous (II) chloride tetrahydrate (FeCl 2 .4H 2 0); 0.177 mL of 37% HCI in 4 mL of DI
water were taken and stirred vigorously in a vortex in 15 mL
centrifuge tube. 1.66 mL of 28-30% NH4 0H solution was
dissolved in 31 mL of DI water in a conical flask and stirred
vigorously for 5 min. Thereafter, the ferric chloride/ferrous
chloride/RC! solution was suddenly added to the stirring
ammonia solution, and the mixture was stirred again for 30
min with 800 rpm at room temperature in a nitrogen atmosphere to prevent critical oxidation. The black precipitate
formed instantly. After complete stirring the iron oxide nanoparticles were separated by sedimentation at the bottom of the
flask using an external neodymium magnetic field. 15 mL of
the supernatant was decanted and then again the stirring was
continued at 800 rpm. 80 mg oflipoic acid (LA) was added in
20 mL chloroform and was vortexed for 20 min. This lipoic
acid solution was then added to the iron oxide nanoparticle
dispersion shortly. The lipoic acid was used to coat the iron
oxide nanoparticles (FIG. 12). After 4 h of complete stirring,
20 mL of methanol was added to reduce the viscosity of the
aqueous phase and allowed the chloroform based ferrofluid to
settle at the bottom of the container. The clear aqueous phase
was first decanted and then the chloroform part was diluted
again by 10 mL of chloroform. The chloroform residue was
then taken in a separating funnel and washed with water to
neutrality. The chloroform part then taken in a 50 mL conical
vial and dried under vacuum to get the black solid powder.
Thus, lipoic acid-coated iron oxide nanoparticles (LA-IO)
were obtained.
To chemically reduce the disulfide bond of LA-IO to
dithiol groups, 0.2 g of solid black lipoic acid was coated iron
oxide nanoparticles in 50 mL of water/ethanol mixture (1: 1),
then the dispersion was ultra-sonicated for 10 min, followed
by vigorous stirring for another 20 min in ice bath. 0.2 g of ice
cold solution of freshly prepared sodium borohydride was
slowly added to it under vigorous stirring conditions. After
complete addition of the solution, the stirring was continued
for another 2 h. The black materials were then separated by
sedimentation using a strong neodymium magnet and washed
with DI water to neutrality. The material was then taken in
choloroform and dried under vacuum to get the solid black
dihydrolipoic acid coated iron oxide nanoparticles (DHLAIO). They were used for the next step of reaction as synthesized.
1.3 Synthesis of CdS:Mn/ZnS Quantum Dots (Qdots ).
Dopant based core-shell CdS:Mn/ZnS nanocrystals were
used in this example. The CdS:Mn/ZnS Qdots were synthesized by a water-in-oil (W/O) microemulsionmethodfollowing a published protocol 36 . In brief, cadmium acetate dihymanganese
acetate
drate
(Cd(CH 3 C00) 2 .2H 2 0),
tetrahydrate (Mn(CH 3 C00) 2 .4H 2 0), sodium sulfide (Na2 S),
and zinc acetate dihydrate, metal basis (Zn(CH 3 C00) 2 .
2H 2 0) were used for the preparation ofCd2 + and Mn2 +; s2 -;
and Zn2 + ion-containing standard aqueous solutions. The
aqueous solution was stirred for 15 min and then added to the
AOT/heptane solutions to form the water-in-oil (W/0) microemulsions. The Mn-doped CdS core nanocrystals were
formed by mixing (Cd2 + and Mn2 +) and s2 - containing

(W/0) microemulsions rapidly for 10-15 min. The W 0 (waterto-surfactant ratio) value ofW/0 microemulsions were maintained at 10. For the growth of outer shell layer on the Mn
doped CdS core Qdots, the Zn2 + ion containing (W/O) microemulsion was added at very slow rate (1.5 mL/min) to the
(W/O) microemulsions containing CdS:Mn. The nucleation
and growth of a separate ZnS phase were suppressed by the
very slow addition of the Zn2 + containing W/O microemulsion. The [Zn2 +] to [Cd2 +] molar ratio (X 0 ) was 8 for our
study.
1.4 Synthesis of NAC Derivatives of Folic Acid (FA), Drug
(STAT3 Inhibitor) and Ethylenediamine (EDA).
Folic acid, drug (STAT3 inhibitor) and ethylenediamine
(EDA) were separately conjugated to NAC following standard bioconjugation techniques as described below.
a) STAT3-NAC Conjugation: A 2 mL anhydrous DMSO
solution containing 3xl0- 5 mo! of N-acetyl cysteine, 5.7x
10-4 mo! ofEDC, and 1.5xl0-4 mo! ofNHS was stirred for 30
min at room temperature. After this incubation, 1.5x10- 5 mo!
of solid STAT3 inhibitor compound (contains secondary nonfunctional amine group) was added and whole solution mixture was stirred for 2 h at room temperature. The reaction
mixture was passed through 0.2 µm Whatman filter membrane and the solution was then dried under vacuum. The
product was dispersed in 1 ml nano pure water (water that has
been deionized and then filtered so that no particles greater
than 1.0 nanometer remain).
b) EDTA-NAC Conjugatation: Following the same procedure as above for STAT3-NAC, a 2 mL anhydrous DMSO
reaction mixture containing 1.2xl0-4 mo! of N-acetyl cysteine, 1.2xl0- 3 mo! ofEDC, and 0.3xl0- 3 mo! of NHS was
stirred for 30 min at room temperature. After this incubation,
1.2xl 0- 3 mo! of ethylenediamine (EDTA) was added and the
whole reaction mixture was then stirred for another 2 h at
room temperature. Then, N 2 gas was passed through it followed by filtration through a 0.2 µm Whatman membrane.
This solution was then dried under vacuum and the dried
product was then dispersed in 1 ml nanopure water.
c) Folic Acid-NAC Conjugation: Following the same procedure as above for STAT3-NAC and EDA-NAC, 2 mL PBS
solution containing 2.8xl0- 5 mo! of folic acid, and 5xl0- 5
mo! of EDC was stirred for 30 min at room temperature. To
this solution, 0.5 ml of the NAC-EDA complex was added.
The resulting reaction mixture was then stirred for overnight
in dark at room temperature. The reaction mixture was then
passed through a 0.2 µm cut-off Millipore® membrane filter.
This solution was then dried under vacuum and finally dispersed in nanopure water.
1.5 Synthesis ofQdots Attached to Iron Oxide Nanoparticles
(IONPs-Qdots)
In this synthesis process, the CdS:Mn/ZnS core-shell
quantum dots (Qdots) were extracted from the microemulsion solution by repeated centrifugation followed by washing
several times with methanol and ethanol. The extracted Qdots
were dispersible in DI water and used as extracted from
microemulsion solution. To the 1 mL Qdots dispersion (20
mg/mL) in water, the DHLA-coated IONP dispersion (2
mg/mL) in 4 mL ethanol was added dropwise. After complete
addition, the whole reaction mixture was stirred for overnight. Thereafter, the nanoparticles were separated by a
strong external neodymium magnet and washed several times
with ethanol and DI water to remove the unused Qdots. In this
way, the Qdots were attached on the surface ofIONPs through
a DHLA linker. The attachment of Qdots on the IONP surface, however, partially reduced the brightness of the Qdot
luminescence. The IONP-Qdot composites were bright
enough to be easily visualized under illumination by a hand-
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held 366 run multiband UV light source. Furthermore, the
IONP-Qdot composites responded well to external magnetic
fields.
1.6 Surface Functionalization of IONPs-Qdots
The 2 mg/mL IONPs-Qdots nanoparticles were taken in
DMSO/ethanol (4: 1) mixture and stirred, as well as sonicated
to be well dispersed. This dispersion was showing fluorescence under hand-held 366 run multiband UV light source.
This dispersion was then added to a mixture of 0. 7 ml of drug
(STAT-3)-NAC, 0.2 ml ofEDA-NAC and 0.4 ml ofFA-NAC
conjugates slowly under constant vortexing and UV exposure. It was observed that the previous fluorescence intensity
of the IONP-Qdot conjugates was quenched. The reaction
was stirred for overnight and then the whole conjugated nanocomposites were separated by a strong external neodymium
magnet and washed several times with DMSO and nanopure
water. Finally, the reaction mixture was dispersed in 1 ml of
0.1 (M) NaHC0 3 solution and stirred for few minutes in dark.
After this stirring, 5.5 mg of methyl-PEG-NHS ester was
added to it and the whole solution was stirred for overnight.
These activatable multifunctional/multimodal composite
nanoprobes (MMCNPs) were then separated by an external
neodymium magnet and washed several times with DPBS
(Dulbecco' s phosphate buffered saline), and finally was taken
in DPBS for further use.
1.7 Preparation of MRI Samples
Human breast cancer (MDA-MB-231), pancreatic cancer
(Pane-I), and mouse thymus stromal epithelial (TE-71) cells
have all been previously reported31 •32 . Cells were grown in
Dulbecco's modified Eagles's medium (DMEM) containing
10% heat-inactivated fetal bovine serum. Cells were treated
with the nanoparticles set forth in section 1.6 above at a
concentration of 0.1 mg/ml for 24 hours The medium was
extracted by vacuum, and cells were washed by 1xPBS buffer
for 6 times to remove the unbound nanoparticles. Cells were
detached by Trypsin with 0.25% EDTA, centrifuged down at
1500 rpm for 3 minutes and then discarded supernatant. Cells
were then resuspended in sterile water and mixed with equal
volume 3xPBS and 3% agarose, and carefully poured into 10
mm NMR tubes. Positive control was prepared by mixing 0.3
mg/ml nanoparticles solution with equal volume of 3xPBS
and 3% agarose.
1.8 Magnetic Resonance Imaging
Magnetic resonance imaging of a layered cell phantom was
performed at 14T magnetic field strength using Paravision
3.0.2 software and a 10 mm microimaging coil (Bruker). A
three-dimensional gradient echo scan sequence (FLASH)
was acquired with following settings; repetition time (TR)=
200 ms, echo time (TE)=2.7 ms, 128x128x128 matrix size
and field of view (FOV)=10x10x20 mm3 . Hypointense signal
from clusters of iron oxide containing cells, was inverted and
assigned a red pseudocolor for image presentation on subsequent 3D renderings performed using OsiriX viewing software (http://www.osirix-viewer.com).
1.9 CyQUANT™ Cell Proliferation Assay
Human breast cancer (MDA-MB-231) cells, mouse thymus epithelial stromal (TE-71) cells, and pancreatic cancer
(Pane-I) cells were grown in Dulbecco's modified Eagles's
medium (DMEM) containing 10% heat-inactivated fetal
bovine serum. 5000 cells per well were cultured in 96-well
plates. The cells were treated with nanoparticles, compounds
(drug), and nanoparticles conjugated to compound for 24
hours. Cyquant cell proliferation assays (Invitrogen Corp/
Life Technologies Corp, Carlsbad, Calif.) were then performed on each microplate well. The medium was removed
by vacuum, and 50 µL 1x dye binding solution were added to
each mi crop late well, which were then incubated at 3 7° C. for

30 minutes. The fluorescence intensity of each sample was
measured using a fluorescence microplate reader (POLARstar Omega, BMG Labtech, Durham, N.C., USA) with
excitation at about 485 run and emission detection at about
530run.
1.10 Confocal Fluorescence Microscopy
The cells were fixed on the glass slide after 24 hrs of
incubation with the nanoparticles, compounds (drug), and
nanoparticles conjugated to compound. Confocal fluorescence miscroscopy on the cells was done with a home-built
sample-scarming confocal microscope. The excitation source
was 375 run pulse diode laser (PicoQuant GmbH, LDH-P-C375). The power used was 3nW. The laser was focused on a
spot size of -300 run with a Zeiss lOOx Fluar objective lens
(NA 1.3, WD 0.17 mm). The sample was raster scanned using
a piezoelectric stage (Mad City Labs, Nano-LP! 00) to get the
fluorescence images of the cells with the quantum dots. The
fluorescence was detected using the avalanche photodiode
(PerkinElmer SPCM-AQR-14). The spectra were collected
using a spectrograph with a grating (150 g/mm, blaze: 500
run) centered at 600 run (PI Acton SP-2156), which was
coupled to a thermoelectrically cooled Electron Multiplying
Charge Coupled Device (EM-CCD Andor iXon EM+
DU-897 BI). Spectra were collected from different spots on
the cells. Each spectrum was collected with 10 sec exposure
time and with three consecutive exposures. These spectra
were then averaged in a home-written Matlab program
(Mathwork Inc. Natick, Mass.). After taking 100 averaged
spectra, they spectra were compiled and an ensemble spectrum was built in Matlab program. The corresponding bright
field images were taken by using the same spectrograph with
grating (1200 g/mm, blaze: mirror) centered at 4 run and
coupled with EM-CCD. The exposure time for bright field
image was 0.05 sec.
1.11 UV-Vis and Fluorescence Measurements
The UV-Vis absorption spectra were collected by using 1
cm path length quartz cuvette with an Agilent 8453 spectrometer. The fluorescence emission spectra were taken by using
the 1 cm path length quartz cuvettes with a N analog™ Horiba
Jobin Yvon fluorometer. The excitation and emission slits
were 5 run. The excitation wavelength was 375 run for quantum dots and 300 run for the drug (STAT3 inhibitor (SF-1046, drug).
In 2 mL of PBS, 100 µL quantum dots in PBS were added
and the absorption and emission was taken. Thereafter, 50 µL
of 0.3 M solution of GSH was added and absorption and
emission spectra were collected immediately after addition of
GSH and after every 5 min up to 60 min. This gave a plot of
"-max emission vs. time in min. After 35 min, the fluorescence
was nearly constant showing that the drug is completely
released after 35 min.
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In this example, two different water-soluble biomolecules,
the N-acetyl cysteine (NAC) and the glutathione (GSH), were
used as surface coating ligands for the Qdot nanoparticles.
This includes a single-step, one-part synthesis where the Qdot
nanocrystals were grown in the presence of the biomolecules.
These Qdots were characterized by fluorescence spectroscopy. Stability of the GSH-coated Qdots and the NAC-coated
Qdots were studied by treating the coated Qdots with ethylenediaminetetraacetic acid (EDTA, a strong chelating agent
for Zn and Cd ions). The results show that fluorescence properties of Qdots are affected by the type of surface coated
ligands. In comparison to the GSH-coated Qdots, the NACcoated Qdots show broad, but strong emission towards near
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infra-red region. When treated with EDTA, the fluorescence
property of the GSH-coated Qdot was affected less than the
NAC-coated Qdots. This preliminary study shows that NACcoated Qdots could thus potentially be used to develop activatable ("OFF/ON") probes for potential deep-tissue imaging
applications, the GSH-coated Qdots could thus be applied for
probing desired analytes or for bioimaging purposes in environmentally harsh conditions.
2.1 Preparation ofGSH-Coated Qdots
A water-in-oil (W/O) microemulsion technique was used
to synthesize GSH-coated CdS:Mn/ZnS Qdots at room temperature. The W/O microemulsion system consisted of dioctyl sodium sulfosuccinate (called Aerosol OT or AOT-a
surfactant), heptane (oil) and water (as an aqueous phase).
Acetate salts of bivalent cadmium, zinc and manganese were
using as an ionic source. In a typical procedure, three separate
aqueous stock solutions containing acetate salts were prepared using DI water first; Solution A-10.0 mL aqueous
solution containing cadmium acetate dihydrate (258.5 mg),
7.4 mg manganese acetate tetrahydrate and 15 mg of GSH;
Solution B-5.0 mL aqueous solution containing 257.5 mg
sodium sulfide and Solution C-5 mL aqueous solution containing 285.3 mg zinc acetate dihydrate. Next, 35 mL of AOT
stock solution was prepared by dissolving 4.46 g of AOT in
heptane under magnetic stirring for about 30 mins. Then,
solution Al was prepared by mixing 0.18 mL of stock SolutionA with 5 mL of AOT/heptane solution, Solution Bl was
prepared by mixing 0.54 mL of stock Solution B with 15 mL
of AOT/heptane solution and Solution Cl was prepared by
mixing 0.54 mL of stock Solution C with 15 mL of AOT/
heptane solution.
Solutions Al, B 1 and Cl were then magnetically stirred for
1 hour. Solution Al was then added to Solution Bl and the
resulting mixed solution (Solution AB 1) was stirred magnetically for 15 mins. SolutionABl was addeddropwise (using a
burette) at a rate 2-3 mL per min to the Solution Cl under
magnetic stirring. To obtain maximum brightness from
Qdots, this solution mixture should be stirred for 7 days at the
room temperature. The GSH-coated CdS:Mn/ZnS Qdots
were then isolated from the W/0 microemulsion system after
precipitating them first using 95% ethanol, followed by
repeated washings ( 6-7 times) with ethanol and ethanol-water
mixture to remove surfactants, any un-reacted ions and excess
GSH. Ultra-centrifugation technique was used between two
successive washing steps to isolate GSH-Qdots in the pellet
form from the solution. The NAC-coated Qdots were similarly prepared by adding 15 mg of NAC in Solution A (in
place of 15 mg GSH). All the chemicals, reagents and solvents were purchased from Aldrich-Sigma and used without
any further purification. The Barnstead Nanopure DI water
was used to prepare all the aqueous solutions. Both GSHQdots and NAC-Qdots were dispersed well in DI water.
2.2. Fluorescence Study
Both GSH-Qdot and NAC-Qdot exhibited bright yellow
emission when exposed to a hand-held UV illumination.
2.3. Excitation ofGSH-Qdots
The GSH coated Qdots emits at-620 nm upon excitation at
3 7 5 nm. In comparison to the NAC-Qdot, the GSH-Qdots are
moderately bright. FIG. 20 shows the effect of increase of
EDTA concentration on the fluorescence intensity of GSHQdot in DI water at the room temperature. No significant
change in the fluorescence intensity was observed. Initially,
there was a slight quenching (i.e. decrease in the fluorescence
intensity) followed by restoration of fluorescence intensity to
its initial value. This data suggest that EDTA has minimal
effect on the stability of GSH-Qdots, even though EDTA is
known to form stable water soluble complex with both the

zinc and cadmium ions. The GSH-Qdot fluorescence is however quenched by the copper ions. FIG. 21 shows the effect of
increase of Cu ion concentration on the fluorescence intensity
ofGSH-Qdots. A steady decrease in the fluorescence intensity was observed with the increase in the Cu ion concentration. The inset of the FIG. 21 shows the linear relationship
between the fluorescence intensity and the Cu ion concentration. While not wishing to be bound by theory, our results
suggest that Cu ions are possibly reacting with the Qdots,
forming copper sulfide on the Qdot surface. Due to this
chemical transformation the microenvironment of Mn is
altered, resulting in the creation of surface related defects.
Such defects could result in the increase of non-radiative
processes and fluorescence quenching.
2.4 Preparation ofNAC-Qdots
The NAC-coated Qdots are highly soluble in DI water and
they exhibit extremely bright fluorescence properties. A very
broad fluorescence emission in the range 525 nm -800 nm was
observed. This broad emission could have been originated
due to NAC-induced surface-related defects. FIG. 22 shows
the effect of increase of EDTA concentration on the fluorescence intensity ofNAC-Qdots. A steady decrease in the fluorescence intensity was observed upon increase in the concentration ofEDTA. This observation suggests that NAC-Qdot is
not stable against the EDTA chelator. The fluorescence
quenching could be due to direct binding of EDTA to the ZnS
surface and/or replacement of the NAC by the EDTA. It is
well known that EDTA forms a stable complex with Zn ions.
A similar observation (i.e. steady decrease in the fluorescence
intensity) was made when the NAC-Qdot was exposed to the
increasing concentration of Cu ions (FIG. 23). This may be
attributed to the formation of Cu sulfide on to the Qdot surface.
In summary, we have described a simple but robust method
of making water-soluble CdS:Mn/ZnS at the room temperature. Both the GSH and the NAC are capable of coating Qdot
surface via conjugation through their sulfhydryl (-SH)
groups and thus forming hydrophilic Qdots. The GSH Qdots
are more stable than NAC-Qdots when challenged against a
strong chelator, EDTA. The Cu ions are able to quench fluorescence of both the GSH-Qdot and the NAC-Qdot, suggesting the formation of copper sulfide on to the Qdot surface. The
NAC-Qdot emission band is broader than the GSH Qdots.
Therefore, NAC-Qdots may be used for NIR imaging of
biological tissues using two-photon excitation. Our study
suggests that NAC-Qdots could be an attractive choice for the
fabrication of activatable ("OFF/ON") Qdots for bioimaging
and sensing applications.
While various embodiments of the present invention have
been shown and described herein, it will be obvious that such
embodiments are provided by way of example only. Numerous variations, changes and substitutions may be made without departing from the invention herein. Accordingly, it is
intended that the invention be limited only by the spirit and
scope of the appended claims.
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The invention claimed is:
1. An optically activatable nanoprobe comprising:
an inorganic core;
a quantum dot linked to the inorganic core; and
at least one ligand linked to the quantum dot, the at least
one ligand effective to reduce luminescence of the quantum dot when linked thereto.
2. The optically activatable nanoprobe of claim 1, wherein
the at least one ligand comprises at least one of an active
~gen~, a targeting agent, a hydrophilic dispersing agent, an
1magmg agent, or combinations thereof.
3. The optically activatable nanoprobe of claim 2, wherein
the at.least one ligand comprises each of an active agent, a
targetmg agent, and a hydrophilic dispersing agent.
4. The optically activatable nanoparticle of claim 3
wherein the active agent comprises a STAT-3 inhibitor th~
targeting agent comprises folate, and the hydrophilic dis;ersing agent comprises polyethylene glycol.
5. The optically activatable nanoprobe of claim 1, wherein
the at least one ligand comprises a hydrophilic dispersing
agent.

6. The optically activatable nanoprobe of claim 5, wherein
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the quantum dot comprises a coating of the hydrophilic dispersing agent.
7. The optically activatable nanoprobe of claim 1, wherein
the hydrophilic dispersing agent comprises at least one of
N-acetyl cysteine and glutathione.
8. The optically activatable nanoprobe of claim 1, wherein
the at least one ligand is linked to the quantum dot by
N-Acetyl-L-Cysteine.
9. The optically activatable nanoprobe of claim 1, wherein
the inorganic core comprises iron oxide, and wherein the
quantum dot comprises a CdS:Mn/ZnS quantum dot.
10. The optically activatable nanoprobe of claim 1
~he_rein the quantum dot is linked to the inorganic core by ~
hnkmg group, and wherein the linking group comprises a
hetero-bifunctional cross-linking molecule.
11. The optically activatable nanoprobe of claim 10,
wherein the linking group comprises dihydrolipoic acid.
12. The optically activatable nanoprobe of claim 1
wherein the at least one ligand is linked to the quantum dot b;
a disulfide bond.
13. The optically activatable nanoprobe of claim 1
wherein the nanoprobe has a particle size of from 20-40 nm'.
. 14. An optically activatable nanoprobe for monitoring
mtracellular drug delivery comprising:
a core component; and
at least one ligand linked to the core component, the at least
one ligand comprising at least one of an active agent, a
~argeting agent, an imaging agent, a hydrophilic dispersmg agent and combinations thereof, the at least one
ligand being effective to reduce luminescence of the of
the quantum dot when linked thereto.
15. The optically activatable nanoprobe of claim 14
wherein the core component comprises an iron oxide core and
a plurality of quantum dots linked to the inorganic core.
16. The optically activatable nanoprobe of claim 14,
wherein the core component comprises a quantum dot.
17. The optically activatable nanoprobe of claim 14
wherein the core component comprises a quantum dot and ~
chitosan polymer.
18. The optically activatable nanoprobe of claim 17
wherein the chitosan polymer further comprises a hydrophili~
dispersing agent.
19. The optically activatable nanoprobe of claim 14, fur~her comprising a lipid vesicle at least partially or fully encasmg the core component and the at least one ligand.
20. The optically activatable nanoparticle of claim 14
wher~in the at least one ligand comprises an active agent, ~
targetmg agent, and a hydrophilic dispersing agent, wherein
the active ag.ent comprises a STAT-3 inhibitor, the targeting
agent compnses folate, and the hydrophilic dispersing agent
comprises polyethylene glycol or derivatives thereof.
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